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Prion disorders and Alzheimer´s disease (AD) both belong to the group of neurodegenerative
diseases and share distinct neuropathological patterns. The key event in prion diseases, such
as Creutzfeldt-Jakob disease (CJD) in humans or bovine spongiform encephalopathy (BSE) in
cattle, is the conversion of the host encoded cellular prion protein (PrPc) to the disease
associated misfolded isoform PrP scrapie (PrPSc), predominantly accumulating in the brain. In
AD the causative agent and the main component of the amyloid plaques is the Amyloid β
peptide, emerged from the enzymatic processing of the Amyloid β precursor protein (APP).
These protein aggregates lead to neuronal death of the affected individual. So far, there is no
therapy available to cure or stall the progression of both diseases, although a lot of efforts
have been driven to develop curative or palliative therapies.
Recently, the 37kDa/67kDa non-integrin laminin receptor LRP/LR has been identified as a
receptor for the cellular prion protein and the pathogenic isoform PrPSc. Fluorescent labeled
LRP- and PrP-molecules co-localize on the cell surface and in the perinuclear compartment.
Furthermore, a fluorescent PrP-mutant lacking the signal sequence partly co-localizes with
fluorescence labeled LRP in the nucleus. These results implicate an involvement of LRP/LR
in the cellular trafficking of the prion protein.
A series of therapeutic strategies for the treatment of prion diseases targeting LRP/LR have
been conducted. Downregulation of LRP/LR by RNAi and the generation of a laminin
receptor decoy mutant represent alternative promising approaches. Microinjection of lentiviral
vectors encoding for siRNAs directed against the LRP mRNA into the hippocampus resulted
in a significant prolongation of the pre-clinical phase in scrapie infected mice. Transgenic
mice expressing a laminin receptor decoy mutant show a significantly prolonged incubation
time after prion inoculation. Therefore, LRP/LR represents a promising molecular target for
the development of prion disease therapeutics.
Very recently, PrPc has been shown to directly regulate β-secretase activity, which
participates in the amyloidogenic cleavage process of APP, generating the soluble APPβ
(sAPPβ) and the AD-associated Amyloid β peptides (Aβ). Furthermore, PrPc mediates
impairment of synaptic plasticity by amyloid-β oligomers. The prion receptor LRP/LR, PrPc
and APP all localize at the cell surface. Treatment of HEK293FT cells with the LRP/LR-
specific antibody IgG1-iS18 resulted in a significant reduction of the Aβ release and the
sAPPβ shedding by 99%, respectively, suggesting that LRP/LR contributes to both processes
by promoting the β-secretase. LRP/LR specific pharmaceuticals such as antibodies may have
therapeutic potential for the treatment of Alzheimer’s Disease.
Chapter I
Therapeutic approaches for prion disorders
published as:
Ludewigs, H., Zuber, C., Vana, K., Nikles, D., Zerr, I. and Weiss, S., Therapeutic approaches
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Veterinary Microbiology 123 (2007) 387–393Therapeutic approaches targeting the prion receptor LRP/LR
Chantal Zuber, Heike Ludewigs, Stefan Weiss *
Laboratorium fu¨r Molekulare Biologie-Genzentrum, Institut fu¨r Biochemie der Ludwig-
Maximilians-Universita¨t Mu¨nchen, Munich, GermanyAbstractTransmissible spongiform encephalopathies known as prion diseases are a group of fatal neurodegenerative disorders that
affect both humans and animals. The generally accepted principle of the disease is that the conversion of the cellular prion
protein (PrPc) into the disease associated isoform PrPSc leads to spongiform degeneration of the brain and amyloid plaque
formation. Until now no therapy leading to potential alleviation or even cure of the disease exists. It is therefore important to
develop therapeutic approaches for the treatment of TSEs since these infections are inevitably fatal and, especially in the case of
vCJD, they affect youngsters. Besides current conventional therapeutic strategies, this review summarizes new therapeutic tools
targeting the prion receptor LRP/LR.
# 2007 Elsevier B.V. All rights reserved.
Keywords: Bovine spongiform encephalopathy; 37 kDa/67 kDa laminin receptor; LRP/LR; Prion; PrP; Transmissible spongiform
encephalopathy; Therapy1. Introduction
Prion diseases or TSEs are neurological disorders
associated with the aggregation of a pathologic
isoform of a host-encoded prion protein (PrP).
Conversion of the cellular prion protein (PrPc) into
the disease-associated form PrPSc leads to conforma-
tional changes resulting in aggregation and accumula-
tion. Deposition of this abnormal protein takes place
mainly in the brain and the lymphoreticular system,
accompanied with neuronal vacuolation (spongiosis)
and neuronal death. After extremely long incubation
times, affected individuals show progressive neuro-* Corresponding author. Tel.: +49 89 2180 76887;
fax: +49 89 2180 76999.
E-mail address: weiss@lmb.uni-muenchen.de (S. Weiss).
0378-1135/$ – see front matter # 2007 Elsevier B.V. All rights reserved
doi:10.1016/j.vetmic.2007.04.005logical symptoms terminating in death. Conventional
therapeutic approaches use anti-prion compounds
which can prolong incubation times but do not lead
to a cure. It has been demonstrated that prion
propagation in vitro requires the laminin receptor
(Leucht et al., 2003) implicating that approaches
downregulating LRP/LR are a promising alternative
strategy for the treatment of prion diseases.2. Prion diseases in humans and animals
Prion diseases involve rapid neurological decline,
accompanied by neuronal loss and spongiform
changes caused by accumulation of the aggregated
and misfolded prion protein. The most common type.
C. Zuber et al. / Veterinary Microbiology 123 (2007) 387–393388of human prion diseases, termed Creutzfeldt-Jakob
disease (CJD), can be classified into four categories:
sporadic (sCJD), inherited/familial (fCJD), iatrogenic
(iCJD) and variant (vCJD). Whereas it has been
suggested that the latter results from ingestion/
consumption of BSE-contaminated food (Bruce
et al., 1997), familial disorders (fCJD) are the
inheritance of autosomal-dominant mutations within
the Prn-p locus. Transplantation of tissues or injection
of hormones originating from individuals suffering
from CJD or the use of contaminated surgical
instruments resulted in the iatrogenic form of CJD.
Gerstmann–Stra¨ussler–Scheinker syndrome (GSS),
fatal familial insomnia (FFI), its sporadic form (sFI)
and kuru are other human prion diseases.
Animal TSEs have been observed in different
species: Bovine spongiform encephalopathy (BSE) in
cattle, scrapie in sheep and goat, chronic wasting
disease (CWD) in cervids such as deer, elk or captive
mule and feline spongiform encephalopathy (FSE) in
cats or transmissible mink encephalopathy (TME). In
addition, some exotic diseases were observed includ-
ing exotic ungulate encephalopathy (EUE) and
primate spongiform encephalopathy (PSE). Transmis-
sion of BSE to pigs has been experimentally proven
(Wells et al., 2003). Recently, new forms of TSEs with
unusual characteristics e.g. an atypical scrapie case
(Nor98) (Benestad et al., 2003) have been discovered.
Apart from the existing species barrier, the different
modes of transmission are not yet understood.3. Prions and different forms of prion proteins
The term prion was defined by Stanley Prusiner as a
‘‘small proteinaceous particle that resists inactivation
by procedures which modify nucleic acids’’, suggest-
ing that a new agent exists beside the commonly
known pathogenic organisms such as bacteria, virus or
fungi (Prusiner, 1982). The infectious ‘‘agent’’, the
prion, and the exact infectious mechanism for prion
disorders is just as little understood as the mechanism
by which they kill neurons.
PrPc is an ubiquitous membrane-bound glycoprotein
attached to the cell surface by a glycosylphosphatidy-
linositol (GPI) anchor, expressed in many tissues and
cell types. Its conversion leads to the disease-associated
form PrPSc, which exhibits a higher b-sheet contentcorrelating with a high tendency to form aggregates.
PrPSc is characterized as insoluble and partially
resistant to proteases (Cohen and Prusiner, 1998).
Digestion of PrPc with protease K results in the
truncated form PrPres (a 27–30 kDa fragment) demon-
strating insolubility in aqueous and organic solvents as
well as in non-ionic detergents. Additionally, it is
completely resistant to proteases. PrPSc and PrP27-30
both have the tendency to form amyloid fibrils.4. The 37 kDa/67 kDa LRP/LR as the receptor
for PrPc
In a yeast two-hybrid screen we identified the
37 kDa laminin receptor precursor (LRP) as an
interaction partner for the prion protein (Rieger
et al., 1997). Further in vitro studies on neuronal
and non-neuronal cells proved that both the 37 kDa
LRP and the 67 kDa high affinity laminin receptor
function as the receptor for the cellular prion protein
(Gauczynski et al., 2001). Direct and indirect heparan
sulphate proteoglycane (HSPG)-dependent binding
domains on LRP/LR and on PrP have been identified
suggesting that HSPGs act as co-factors or co-
receptors for PrPc (Hundt et al., 2001). It has been
suggested that the 37 kDa LRP is the precursor of the
67 kDa form which was first isolated 1983 from
melanoma cells due to its high binding capacity to
laminin (Rao et al., 1983). The relationship between
the 37 kDa precursor form and the mature 67 kDa
isoform is still unknown. Regarding the function of
LRP/LR, the 37 kDa LRP appears to be a multi-
functional protein involved in the translational
machinery (Auth and Brawerman, 1992) and has also
been identified as a ribosome-associated protein
termed p40 (Makrides et al., 1988). LRP has also
been localized in the nucleus, where it is closely
associated with nuclear structures (Sato et al., 1996)
and binds to DNA through connections with histones
H2A, H2B and H4 (Kinoshita et al., 1998). The
37 kDa/67 kDa LRP/LR has been described as a
receptor for laminin, elastin and carbohydrates (Ardini
et al., 1998), as well as a receptor for Venezuelan
equine encephalitis virus (VEE) (Ludwig et al., 1996),
Sindbis virus (Wang et al., 1992), Dengue virus (Tio
et al., 2005) and Adeno-Associated Viruses (Akache
et al., 2006). In addition, studies have been carried out
C. Zuber et al. / Veterinary Microbiology 123 (2007) 387–393 389in order to detect the isoforms that are present in the
central nervous system and that bind PrP. Several
maturation states of the receptor were identified,
including a 44 kDa, 60 kDa, 67 kDa and a 220 kDa
form. All of these isoforms were able to bind PrP,
suggesting a physiological role for the laminin
receptor/PrP interaction in the brain (Simoneau
et al., 2003). Although LRP consists of a transmem-
brane domain (amino acid residue 86–101 (Castro-
novo et al., 1991)) it is abundant in the cytoplasm
(Romanov et al., 1994). In mammalian cells both the
37 kDa LRP and the 67 kDa LR are present in plasma
membrane fractions (Gauczynski et al., 2001).5. The role of LRP/LR in PrPSc propagation
LRP/LR not only acts as a receptor for the cellular
prion protein but also for the infectious PrP27-30, an
N-terminal truncated version of PrPSc (Gauczynski
et al., 2006). The importance of LRP/LR in PrPSc
propagation was verified using a polyclonal anti-LRP/
LR antibody termed W3 which was able to block and
prevent the binding of PrPSc and to cure scrapie-
infected neuroblastoma cells (ScN2a) from PrPSc
(Leucht et al., 2003).
LRP/LR-dependent binding of PrPc and PrPSc to
the cell surface (either alone or together with other co-
factors) is accompanied by internalisation which is
thought to occur in clathrin-coated pits. After this
receptor-mediated endocytosis the conversion of PrPc
molecules into the disease-associated form probably
takes place in endosomes, lysosomes or endolyso-
somes. Heparan sulphates also play an essential role in
prion uptake and cell infection (Horonchik et al.,
2005) suggesting that both the LRP/LR and heparan
sulphates act presumably in synergy for PrPSc binding
and internalisation.
The fact that LRP/LR is present in higher amounts
in several organs and tissues of scrapie-infected mice
and hamsters suggests a correlation between LRP/LR
levels and PrPSc propagation (Rieger et al., 1997).
Furthermore, expression studies revealed distribution
of the laminin receptor in the intestinal epithelial/
brush border confirming that the prion protein uptake
and therefore the infection is mediated and supported
by this receptor (Shmakov et al., 2000). After oral
exposure, TSE agents accumulate in lymphoid tissue,spleen, lymph nodes, tonsils, appendices and Peyer’s
patches. For this reason prion particles have to cross
the intestinal epithelial barrier. Besides the proposition
that M-cells are responsible for the uptake of prions
(Heppner et al., 2001) has also been suggested that
enterocytes are involved in this process, due to the fact
that bovine prions are rapidly endocytosed in the
presence of LRP/LR (Morel et al., 2005). By
preincubating the human enterocytes with the poly-
clonal anti-LRP/LR antibody, endocytosis of PrPBSE
was reduced.
Distribution studies in adult rats revealed that the
67 kDa LR form is highly present in brain regions,
classically associated with prion-related neurodegen-
eration, whereas the 37 kDa form was detected in a
subclass of interneurons known to be particularly
sensitive to abnormal prion accumulation and cell
death during the early stages of CJD (Baloui et al.,
2004).6. Conventional therapeutic strategies for the
treatment of TSEs
In recent years, various studies gave evidence that
substantial neuropathological changes (e.g. nerve cell
degeneration) already occur prior to the onset of
symptoms and might be related to PrPSc accumulation.
Accordingly, any effective intervention must aim to
start directly after inoculation. Unfortunately, no
diagnostic tests are available to detect the disease
prior to the onset of symptoms, except for individuals
carrying pathogenic mutations within the Prn-p gene.
Inhibition of PrPSc formation is the most studied target
and can be achieved through (i) inhibition of PrPc
synthesis or prevention of its transport to the cell
surface, (ii) stabilization of the PrPc structure to make
its conformational change unfavourable, (iii) destruc-
tion of PrPSc aggregates, (iv) reversion of PrPSc to a
protease-sensitive form and (v) inhibition of the prion
protein receptor(s).
A series of compounds efficiently interfere with
PrPSc accumulation, such as Congo red (Ingrosso
et al., 1995) and analogs (Demaimay et al., 1997),
certain cyclic tetrapyrrols (Priola et al., 2000) and
sulphated polyanions. Although many other com-
pounds have been identified, only flupirtine, an
analgetic, had beneficial effects on cognitive function
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anthracycline 40-iodo-40-deoxy-doxorubicin (IDX)
was able to delay clinical signs of the disease and
prolong the survival time in scrapie-infected hamsters
(Tagliavini et al., 1997). It was also shown that
quinacrine reduces the protease resistance of PrP
peptide aggregates and is able to inhibit the in vitro
conversion of the normal prion protein (PrPc) to the
abnormal form (PrPres) (Barret et al., 2003).
Chlorpromazine was reported to increase incubation
time in mice after intracerebral, but not intraperito-
neal, injection (Roikhel et al., 1984), but was less
effective in cell culture than quinacrine (Korth et al.,
2001). Unfortunately, most substances that inhibit
PrPSc formation show only significant effects when
administered long before the clinical onset of the
disease. Since no effective therapy for clinically
affected TSE patients is available these diseases are
inevitably fatal.
PrP-specific antibodies, a promising alternative
tool in TSE treatment, counteract prion propagation
both in vitro (Enari et al., 2001; Peretz et al., 2001;Fig. 1. Molecules inhibiting the PrP-LRP interaction and reducing the LR
protein (green circle) and the infectious PrPSc (green rectangle). After b
internalized into endo-/lysosomal compartments where the conversion of Pr
achieved by (I) trapping PrPSc by a LRP mutant (delTMD) encompassing th
(IIa) siRNAs and (IIb) antisense RNA directed against LRP mRNA, (III) an
binding sites and (IV) heparan mimetics interfering with the binding of PPerrier et al., 2004) and in vivo (Buchholz et al., 2006).
In a murine model, treatment with a monoclonal anti-
PrP antibody delayed the development of prion
disease (White et al., 2003). Application of mono-
clonal antibodies raised against recombinant PrP also
resulted in a reduction of PrPSc levels in infected
mouse neuroblastoma cells (Pankiewicz et al., 2006).
Paracrine secretion of single chain antibodies (scFv)
directed against PrPc revealed an anti-prion effect in
neuroblastoma cells (Donofrio et al., 2005).7. Therapeutic approaches targeting LRP/LR
7.1. Trans-dominant negative LRP mutants
Recently, it has been shown that an LRP mutant
encompassing the extracellular domain of LRP/LR
(LRP102-295::FLAG) might act in a trans-dominant
negative way as a decoy by trapping PrP molecules
(Fig. 1, I) (Vana and Weiss, 2006). In vitro studies
revealed that the LRP mutant is able to reduce theP/LR levels. LRP/LR (orange) is able to bind both the cellular prion
inding to the LRP/LR–HSPG complex the prion protein becomes
Pc to PrPSc might take place. Prevention of the binding to LRP/LR is
e extracellular domain (LRP102-295), downregulation of LRP/LR by
ti-LRP/LR antibodies (blue rectangles) competing with PrP for LRP
rPSc to the LRP/LR/HSPG complex.
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(Vana and Weiss, 2006) and might therefore represent
a promising novel tool in TSE therapy.
7.2. RNA interference and antisense RNA
A further strategy used to influence the PrPSc
propagation level is the knockdown of LRP/LR by
siRNA and antisense RNA technology. This has
already successfully been shown for PrP using Prn-p-
specific sequences. Thus, the transfection of siRNAs
corresponding to the murine Prn-p triggered specific
Prn-p-gene silencing in scrapie-infected neuroblas-
toma cells. This caused a rapid loss of their PrPres
content (Daude et al., 2003). Accordingly, it was
shown that transfection of either LRP antisense RNA
or LRP-specific siRNAs in scrapie-infected neuronal
cells results in downregulation of LRP/LR expression
and prevention of PrPSc propagation (Fig. 1, II)
(Leucht et al., 2003).
Furthermore, a permanent effect of knockdown of
disease-relevant genes using RNAi has been achieved
using a lentivirus-mediated gene transfer (Ralph et al.,
2005; Raoul et al., 2005). Recently it was shown that
lentivector-mediated RNAi efficiently suppressed the
prion protein and prolonged survival of scrapie
infected mice (Pfeifer et al., 2006). This suggests
that an alternative lentivirus-based RNAi gene therapy
approach using HIV-derived vectors expressing LRP-
specific siRNAs might represent another promising
approach in TSE treatment.
7.3. Antibodies directed against the LRP/LR
The PrP binding capacity of LRP offers strategies
in therapeutic approaches against prion diseases. The
curative effect of the polyclonal anti-LRP/LR anti-
body (W3) on scrapie infected N2a cells recommends
anti-LRP antibodies as therapeutic tools for the
treatment of prion diseases (Leucht et al., 2003).
On the molecular level this antibody (i) prevents the
binding of infectious prions to mammalian cells
(Fig. 1, III) (Gauczynski et al., 2006) and (ii) blocks
endocytosis of PrPBSE by enterocytes mediated by the
LRP/LR is inhibited after treatment with W3 (Morel
et al., 2005). Moreover W3 was able to prolong the
incubation/survival time in scrapie mice (Zuber et al.,
submitted).Since a polyclonal antibody format is not suitable
for a therapy in animals or humans the development of
single-chain antibodies directed against LRP/LR
provides a promising alternative therapeutic strategy.
Smaller (30 kDa) and with better tissue penetration,
they can be delivered via passive immunotransfer for
example intracerebrally into the brain region where
massive prion propagation takes place. So far, no
immune response or side reactions have been observed
after application of scFvs. In a murine scrapie model
passively delivered anti-LRP/LR single chain anti-
bodies reduced peripheral prion propagation (Zuber
et al., in press). To circumvent the problem of the short
half-life in organisms a permanent delivery of single
chain antibodies directed against LRP/LR may be
achieved by gene therapeutic strategies employing
AAV-based or lentiviral vector systems.
7.4. Polysulphated glycans
Polysulphated glycans such as heparan mimetics
(HM) or pentosan polysulphate interfere with the
binding of the infectious PrP27-30 to the LRP/LR–
HSPG complex and are therefore alternative promising
therapeutic tools (Fig. 1, IV) (Gauczynski et al., 2006).
Treatment of scrapie-infected mice with pentosan
polysulphate resulted in a prolonged incubation time
and even in the cure of two mouse strains infected with
two different scrapie strains (Farquhar and Dickinson,
1986). Moreover, it has been shown that GAGs (Hijazi
et al., 2005), especially heparan sulphate, (Horonchik
et al., 2005) also act as receptors for the infectious
PrPSc. Polysulphated glycans such as SP54 and PS3
(phycarin sulphate) also show an inhibitory effect on the
binding of PrP27-30 to LRP hyperexpressing BHK
cells (Gauczynski et al., 2006). Both pentosan
polysulphates and heparan sulphate mimetics are able
to prolong the incubation time in rodent models and
interfere with PrPSc propagation in neuronal cells due to
the inhibition of the LRP/LR dependent binding of
prions to target cells.8. Conclusions
So far, there is no TSE treatment available that is able
to cure affected individuals. Alternative therapeutic
strategies targeting LRP/LR might be promising since it
C. Zuber et al. / Veterinary Microbiology 123 (2007) 387–393392acts as the receptor for PrPc and PrPSc. Molecules
targeting the LRP–PrP interaction such as LRP mutants,
LRP/LR-specific antibodies and polysulphated glycans
or tools downregulating the LRP/LR levels such as
siRNAs and antisense RNAs might be effective in the
treatment of prion disorders.Acknowledgments
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Abstract: The 37 kDa/67 kDa laminin receptor (LRP/LR) represents a key player for cell adhesion, is associated with the 
metastatic potential of solid tumors and is required for maintenance of cell viability by preventing apoptosis. LRP/LR acts 
as a receptor for viruses such as Sindbis virus, Venezuelean Equine Encephalitis (VEE) virus, Adeno-associated-viruses 
(AAV) and Dengue Virus, the latter causing 50 to 100 million infections in humans per year. LRP/LR acts further as a 
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surface. The receptor represents an alternative target for therapy of viral infections, cancer and prion disorders and might 
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1. THE 37kDa/ 67kDa LAMININ RECEPTOR LRP/LR 
 In a yeast two-hybrid screen, the 37 kDa laminin receptor 
precursor (LRP) was identified as an interaction partner for 
the prion protein [1]. Coinfection and cotransfection studies 
in insect and mammalian cells confirmed the interaction, and 
led to the assumption that LRP might act as the receptor for 
the cellular PrP [1]. Further in vitro studies on neuronal and 
non-neuronal cells validated the hypothesis and showed that 
the laminin receptor LRP/LR acts as the receptor for the 
cellular prion protein [2]. Using the yeast two-hybrid system 
domains on PrP and LRP have been identified to be involved 
in the PrP-LRP interaction. Two binding domains for LRP 
on PrP were discovered: a direct binding domain 
(PrPLRPbd1, aa144-179) and an indirect one (PrPLRPbd2, 
aa53-93), which depends on the presence of heparan sulfate 
proteoglycans (HSPGs) that function as co-factors or co-
receptors for the binding of PrP
c
 to the LRP/LR [3]. 
Furthermore, the yeast two-hybrid system localized the 
direct PrP-binding domain on LRP between amino acid 
residues 161 and 180 [3] (Fig. 1). A second HSPG-depen-
dent binding site, which has not been identified so far, might 
be located between amino acid 180 and 285. HSPGs are 
multifunctional macromolecules characterized by a core 
polypeptide to which glycosaminoglycans (GAGs) are 
covalently attached and have also been shown to act as initial 
attachment receptors for several viruses (Table 1) and are 
associated with A? deposits in Alzheimer’s disease (AD) [4]. 
 The 37 kDa LRP is thought to be the precursor of the 67 
kDa high-affinity laminin receptor (LR), which was first  
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isolated from melanoma cells due to its high binding 
capacity to laminin [5]. Although the LRP has a trans-
membrane domain (amino acid residue 86-101, [3, 6]) (Fig. 
1), it is abundantly localized in the cytoplasm [7]. In mam-
malian cells, it has been demonstrated that both the 37 kDa 
LRP and the 67 kDa LR are present in plasma membrane 
fractions [2]. The exact mechanism by which the 37 kDa 
precursor forms the mature 67 kDa isoform is up to now still 
unclear. Data from a yeast two-hybrid analysis and a size 
exclusion chromatography on recombinant LRP showed that 
LRP failed to interact with itself [3], which is an argument 
against the hypothesis of a direct homodimerization. 
Analysis of the membrane-bound 67 kDa LR indicated, that 
acylation of LRP might be involved in the processing of the 
receptor [8]. Additional studies suggested that the 67 kDa 
LR might be a heterodimer stabilized by fatty acid-mediated 
interactions [9]. Mammalian genomes contain multiple 
copies of the LRP gene, particularly 6 copies in the mouse 
and 26 copies in the human genome [10]. Sequencing 
revealed that over 50% of the 37 kDa LRP gene copies were 
pseudogenes most probably generated by retrotranspositional 
events. The finding of multiple pseudogenes for the 37 kDa 
LRP might suggest that the accumulation of several copies 
of this gene might have given a survival advantage to the cell 
in the course of evolution [11].  
 Interestingly, the 37kDa LRP appears to be a multi-
functional protein involved in the translational machinery 
[12] and has also been identified as p40 ribosome-associated 
protein [13]. In addition, LRP has been found in the nucleus, 
where it is tightly associated with nuclear structures [14]. 
The 37kDa/67kDa LRP/LR has been described to act as a 
receptor for laminin, elastin and carbohydrates [15] as well 
as a receptor for several viruses [16-19, 103] (Table 1). 













Fig. (1). Functional domains of the 37kDa/ 67kDa laminin receptor LRP/LR. 
LRP/LR consists of 295 amino acids (aa) and belongs to the group of Type II membrane proteins, spanning the plasma membrane once (aa 
86-101) with its C-terminus exposed to the extracellular space. PrP/Laminin and Heparin/Laminin binding sites have been characterized at aa 
positions 161-180 and 205-229, respectively. In addition, the scFv/IgG1 antibody binding site has been mapped to aa 272-280 [47,50]. 
Table 1. General Conspectus of LRP/LR and HSPGs as Initial Attachment Receptors for Viruses 
Viruses using LRP/LR as receptor Reference Viruses using HSPGs as receptors (selection) Reference 
Dengue Virus  
(Serotype 1, 2, 3) 
[18] Adeno-Associated Virus  
(Serotype 1,6) 
[102] 
Sindbis Virus [19, 103] Adenovirus (Serotype 2, 5) [104] 
Venezuelean Equine Encephalitis Virus  [17] Human Papilloma Virus [105] 
Adeno-Associated Virus  
(Serotype 2, 3, 8, 9) 
[16] Hepatitis B Virus 
Hepatitis C Virus 
[106] 
[107] 
  Human Immunodeficiency Virus [108] 
  Murine Leukaemia Virus [109] 
  Herpes Simplex Virus Type 1 [110] 
  Pseudorabies Virus [111] 
 
Recent studies investigated the role of LRP/LR in the 
maintainance of cell viability and it has been shown that 
“knockdown” of the laminin receptor via RNA interference 
induced apoptosis [20]. Furthermore, it has been reported 
that LRP/LR might regulate microgliosis [21] and might 
serve as a binding factor for inflammatory macrophages to 
basement membranes [22]. Due to the co-localization of 
LRP/LR and PrP on the surface of mammalian cells, a 
possible role of LRP/LR for PrP binding and internalization 
was assumed. Using a cell-binding assay with recombinant 
PrP a LRP/LR dependent binding of PrP has been shown [2]. 
The strict LRP/LR specificity for the PrP binding could be 
confirmed in competition assays with different anti-LRP 
antibodies. Furthermore, it has been demonstrated, that the 
PrP internalization process represents an active receptor-
mediated event [2]. Due to the identification of various 
LRP/LR isoforms, additional studies have been performed to 
detect the isoforms that are present in the central nervous 
system and bind PrP. Therefore, mouse brain fractions 
enriched in the laminin receptor were purified and overlay 
assays with recombinant PrP were performed [23]. Several 
LRP/LR isoforms corresponding to different maturation 
states of the receptor were identified, including a 44 kDa, 60 
kDa, 67 kDa and a 220 kDa form. Furthermore, it could be 
demonstrated, that all of these isoforms were able to bind 
PrP, supporting a physiological role for the laminin 
receptor/PrP interaction in the brain [23]. A closer insight 
into the fine cellular distribution of LRP/LR in the central 
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nervous system was reached by using immunohistochemistry 
in adult rat brain [24]. It has been shown, that the 67 kDa LR 
is the major receptor form, which is expressed within the 
cytoplasm and at the plasma membrane in most neurons and 
in a subset of glia cells [24]. In contrast, the 37 kDa LRP is 
much less abundant in adult than in postnatal central nervous 
system and its expression is restricted to a subclass of 
cortical interneurons known to be particularly sensitive to 
abnormal prion accumulation and rapidly degenerate during 
early stages of Creutzfeldt-Jakob Disease (CJD) [25]. Recent 
data indicate that LRP levels are increased in the spinal cord 
microglia after activation by peripheral injury or a traumatic 
lesion [26]. In addition, recent studies showed, that LRP/LR 
is not only involved in the PrP
c
 metabolism, but fullfills also 
a crucial role in prion propagation. Using antisense LRP 
RNA or small interfering (si) RNAs specific for LRP 
mRNA, PrP
Sc
 levels in scrapie-infected neuronal cells were 
reduced indicating a necessity for the laminin receptor 
LRP/LR for PrP
Sc
 propagation in cultured cells [27]. Very 
recently it was reported that microinjection of lentiviral 
vectors expressing siRNAs directed against LRP mRNA into 
the brain prolongs the pre-clinical phase in scrapie-infected 
mice [28]. 
 Due to the facts, that a (natural) infection with prions 
mostly occur via an oral route and that LRP/LR act as 
receptor for prions [2, 29] potential binding sites for PrP in 
the intestinal mucosa were examined. Tissue expression 
studies of the LR in human duodenal and jejunal biopsy 
samples led to the discovery, that this receptor is expressed 
in the apical brush border of small intestinal epithelial cells. 
Employing immunohistochemistry LR expression has also 
been observed in the perinuclear/Golgi apparatus region and 
in the Paneth cell secretory granules [30]. A colocalization 
with PrP
c
 in the perinuclear compartment has recently been 
proven [31]. These findings suggest an involvement of LR in 
both secretory and endocytotic functions of human small 
intestinal epithelium. Moreover, it was speculated that the 
major implication of intestinal expression of the 67 kDa LR 
may be an increased susceptibility to an oral infection with 
prions [30]. It has been demonstrated, that the oral 
transmission of infectious prion particles led to a rapid 
accumulation of PrP
Sc
 in Peyer’s patches [32]. PrP
Sc
 has also 
been detected in enterocytes of the villous epithelium of the 
small intestine of primates after oral exposure to prions [33]. 
Enterocytes represent the major cell population of the 
intestinal epithelium [34] and are known to actively 
participate in endocytosis. Since expression of PrP
c
 was 
demonstrated to be necessary for prion replication, 
expression of the cellular prion protein in the gastrointestinal 
tract has been analyzed and indeed it has been shown that 
PrP
c
 is present in human enterocytes [35]. These results led 
to the hypothesis that enterocytes might play an important 
role for the uptake of infectious prion particles. Previously, it 
has been demonstrated that bovine PrP
Sc
 is internalized by 
human enterocytes via an LRP/LR-mediated endocytosis 
[36]. Association of the laminin receptor with glycolipid-
enriched microdomains in the cell membrane might lead to a 
clustering with other proteins in this region to provide a 
mechanism for internalization [37]. In summary, an 
important role of the 37 kDa/ 67 kDa LRP/LR in mediating 
binding and internalization of the prion protein and its 
involvement in pathological mechanisms was demonstrated. 
2. ROLE OF LRP/LR AS A TARGET IN PRION 
DISEASES 
2.1. Antibodies as Therapeutic Tools 
 Antibodies gained increasing attention in the develop-
ment of therapeutics for human disease. Especially 
monoclonal antibodies are used in clinical trials and many of 
them already obtained the approval from the U.S. Food and 
Drug Administration (FDA) for therapy e.g. in cancer. 
Several anti-prion antibodies harboring different formats 
have already been developed antagonizing prion infection 
[38-42]. However, none of them achieved striking results, 
which render them suitable for application in human 
transmissible spongiform encephalopathies (TSEs). 
 The 37kDa/67kDa laminin receptor represents the 
receptor for the cellular prion protein PrP
c
 [2] and a receptor 
for the infectious PrP
27-30 
[29], implicating that LRP/LR 
might represent a valuable and alternative target for antibody 
development in prion disease therapy [39, 44]. Therefore, 
different antibody formats (Table 2, Fig. 2) directed against 
the LRP/LR have been developed to block or prevent 
binding and internalization of the prion protein and therefore 
a possible infection of cells. 
 A polyclonal anti-LRP antibody termed W3 (Fig. 2) 
reduced the PrP
Sc
 propagation in cell culture [27], hampered 
the binding of BSE prions to human enterocytes [45] and 
prevented the binding of PrP27-30 to mammalian cells [29]. 
Passive immunotransfer of W3 into scrapie infected mice 
significantly reduced peripheral PrP
Sc 
propagation by 66% 
and prolonged the survival of scrapie infected mice 1.8-fold 
[46]. Since the amount of the polyclonal antibody W3 is 
limited, single chain Fv antibodies (scFv) have been selected 
via phage display on recombinant LRP [47]. Due to a 
smaller size (approx. 30 kDa) they display a better tissue 
penetration, might pass the blood brain barrier, and might 
therefore reach the brain, where prions replicate predo-
minantly. Application of the anti-LRP scFv antibody termed 
S18 via passive immunotransfer into scrapie infected mice 
reduced PrP
Sc 
levels in the spleen by approx. 40%, indicating 
that the peripheral propagation is impaired (Fig. 2). The fact 
that incubation times and survival were not prolonged might 
be explained with the low stability and short half life 
(approx. 12 hours in blood) of the scFvs. To circumvent 
these problems, we developed a permanent delivery system 
based on recombinant Adeno-associated viral vectors 
(rAAV). rAAV mediated gene delivery is currently inves-
tigated in clinical trials for human therapy. A recent study 
reported the administration of anti-PrP antibodies into 
scrapie infected mice via rAAV serotype 2, which resulted in 
a delayed onset of disease [48]. Intracerebral injection of 
rAAVs encoding for the anti-LRP/LR scFv antibodies S18 
and N3 into scrapie infected mice efficiently reduced the 
peripheral PrP
Sc
 propagation by approx. 60% and 32%, 
respectively [49]. This remarkable finding can be explained 
by the fact that trafficking of intracerebrally administered 
rAAV to the spleen occurred, resulting in a direct scFv 
expression and secretion [49].  
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 Although scFvs provide better tissue penetration and 
probably pass the blood brain barrier, a full length IgG 
format is much more stable in the organism and displays a 
longer half life up to 21 days. In contrast to the small scFvs, 
only the polyclonal anti-LRP/LR antibody W3 prolonged 
survival in scrapie infected mice. Using an improved version 
of the scFv S18 (iS18), as a template for the antigen-binding 
regions, a full length IgG1-iS18 antibody has been 
engineered [50] and will be applied for prophylaxis and 
treatment of scrapie infected mice expecting a more 
pronounced effect regarding survival. 
 The mode of action of the anti-LRP antibodies as a prion 
disease therapeutic, remains to be further investigated. 
Although an epitope mapping of the anti-LRP antibodies 
scFv S18 and full length IgG1-iS18 exhibits recognition at 
the very C-terminal part of LRP (Fig. 1) and not at the direct 
PrP binding site (aa161-180) [47, 50], the antibodies might 
act through sterical hindrance preventing the binding of 
infectious PrP
Sc
 to the receptor. A full length IgG format 
reveals higher stability in vivo and provides a higher affinity 
to the laminin receptor resulting in a probable more 
permanent prevention of the LRP/LR-PrP
Sc
 interaction. 
2.2. Pentosan Polysulfate  
 Pentosan polysulfate (PPS) is a large polysulfated 
glycane with weak heparin-like activity and has been shown 
to prevent PrP
Sc
 propagation in cell culture models [51]. 
Recently, it has been proposed that PPS functions via 
inhibition of the binding of PrP
Sc
 to LRP/LR [29] (Fig. 2). In 
mouse models, PPS is able to prolong the survival time of 
scrapie infected animals or even cures of the mouse strains 
VM and CBA from 22A and ME7 prions, respectively [52]. 
Furthermore, survival time of scrapie-infected mice was 
increased using a combined treatment of PPS and Fe(III) 
meso-tetra(4-sulfonato-phenyl)porphine [53]. Orally or 
intraperitoneally administered PPS, however, is thought to 
be not strinkingly effective for the treatment of TSEs due to 
the assumed inability of the drug to cross the blood-brain-
barrier [54]. Several case studies for the treatment of vCJD 
in humans were performed showing that delivery of PPS by 
Table 2. Anti-LRP/LR Tools as Therapeutics in Prion Diseases 
Effect in vivo Anti-LRP/LR tools Effect in vitro Application in vivo 
Peripheral PrP
Sc






propagation and cures 










reduced by 40% no prolongation no 
prolongation 




delivery by i.c. 
injection of rAAV 
reduced by 60% no prolongation no 
prolongation 
[49] 
Laminin receptor decoy mutant 






in progress in progress in progress [61] 
Strategies downregulating LRP/LR expression 






n.d. n.d. n.d. [27, 59] 










not prolonged [27, 28] 
Anti-LRP/LR tools blocking or downregulating the 37kDa/67kDa LRP/LR were applied in cell as well as in animal studies to investigate their therapeutic potential in prion diseases. 
i.p. intraperitoneal; i.c. intracerebral, n.d. not determined; ScN2a+ Scrapie infected mouse neuroblastoma cells; ScMNB Scrapie mouse neuroblastoma cells; 
peripheral PrPSc propagation was determined analysing the PrPSc content in the spleen of scrapie infected mice 90 days post infection; incubation time describes the time span from 
the scrapie infection until the mice display the first TSE relevant symptoms (Ataxia of gait, tremor, rigidity in the tail or difficulty righting from a supine position). Survival 
represents the time span from the day one of the four TSE symptoms occur until the day two of these symptoms are observed for three days [43]. 
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chronic intra-ventricular infusion resulted in no definite 
clinical benefits [55, 56]. However, continuous intra-
ventricular treatment of a 22-year-old vCJD patient with PPS 
over a period of 31 month resulted in a prolonged survival 
[57]. In addition, very recently the effect of continuous 
intraventricular infusion of PPS was investigated in seven 
UK patients suffering from human prion diseases. In this 
report, it has been demonstrated that a pentosan polysulfate 
therapy during 6 months extended the mean survival of all 
patients [58]. Nevertheless, further in vivo animal experi-
ments and clinical studies, respectively, are required to 
assess the efficacy of PPS administration in variant 
Creutzfeldt-Jakob Disease (vCJD) and other prion diseases. 
2.3. RNA Interference Approaches 
 Since the 37kDa/67kDa laminin receptor (LRP/LR) has 
been identified to act as the cell-surface receptor for the 
cellular prion protein [2] it was further discovered that 
limited expression of LRP inhibits PrP
Sc
 accumulation in 
scrapie infected neuronal cells (ScN2a and ScGT1) [27]. 
Transfection of ScN2a and ScGT1 cells with vectors 
encoding for antisense LRP mRNA led to elimination of 
LRP expression concomitant with an absence of PrP
Sc
 propa-
gation [27] (Fig. 2). In addition, transgenic mice [tgN 
(NSEasLRP)] were generated showing a reduced LRP/LR 
level in hippocampal and cerebellar brain regions and no 
abnormal behavior compared to control mice [59]. Another 
approach to knock down LRP expression deals with small 
interfering (si)RNAs directed against the LRP mRNA. 
Transfection of ScN2a cells resulted in a strong downregu-
lation of LRP correlating with a complete abolishment of 
PrP
Sc
 propagation 72 hours post transfection [27] (Fig. 2).  
 These findings lead to the conclusion that post-trans-
criptional gene silencing of LRP by RNAi is a promising 
approach to delay PrP
Sc
 propagation. In deed, microinjection 
of lentiviral vectors expressing siRNAs directed against 
(LRP mRNA revealed a prolonged pre-clinical phase 
(incubation time) in scrapie infected mice [28]. 
2.4. Transdominant Negative Laminin Receptor Mutant 
RP102-295::FLAG  
 The expression of cellular PrP (PrP
C
) is a major 















Fig. (2). Therapeutic approaches targeting LRP/LR. 
LRP/LR (oval) has been identified as receptor for cellular (circle) and infectious prions (square). Several strategies can be employed to 
interfere with either the expression of LRP/LR (a, b) or binding of PrPSc (c-f). To ablate LRP/LR expression an antisense RNA (a) and a 
small interfering RNA (b) approach have been used resulting in prevention of PrP
Sc
 propagation in scrapie-infected cells [27]. Microinjection 
of lentiviral vectors expressing siRNAs directed against LRP mRNA significantly prolonged the pre-clinical phase in  scrapie-infected mice 
[28]. Both the polyclonal anti-LRP/LR antibody W3 (immunoglobuline structure) (c) and the single chain (scFv) anti-LRP/LR antibody S18 
(single chain antibody structure) (d) have been shown to interfere with the PrP
Sc
 propagation [27, 46, 47]. In addition, drugs such as pentosan 
polysulfate (PPS) (triangles) (e) were able to reduce PrP
Sc
 binding in vitro [29] possibly due to an inhibition of the LRP/LR-dependent 
binding of prions to the cell. As an alternative therapeutic system, a LRP/LR decoy mutant (LRP102-295::FLAG) (semi-oval) (f) has been 
used to interfere with the PrP
Sc
 propagation in scrapie-infected neuroblastoma cells [61]. 
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represents a promising therapeutic
 
target. However, 
identification of the 37kDa/67kDa laminin receptor LRP/LR 
as the receptor for PrP
C
 [2] and PrP
Sc
 [29, 45] led to an 
alternative target for the development of TSE therapeutics. 
Recently, it has been shown that an LRP mutant 
encompassing only the extra-cellular domain of LRP/LR 
(LRP102-295::FLAG) is secreted into the extracellular space 
and therefore might act in a trans-dominant negative manner 
as a decoy by trapping PrP molecules [61]. Baby hamster 
kidney (BHK) cells expressing and secreting the laminin 
receptor mutant show a reduced binding of PrP 27-30, and in 
scrapie-infected neuronal cells the mutant is able to reduce 
the PrP
Sc
 accu-mulation [61] (Fig. 2). Thus, the 
transdominant negative LRP-mutant might have potential for 
the development of a TSE therapy. An in vivo study with 
transgenic animals expressing the LRP mutant will reveal if 
the decoy mutant efficiently influences incubation time 
and/or survival during scrapie infection. 
3. ROLE OF THE 37kDa/67kDa LAMININ RECEPTOR 
LRP/LR IN ZOONOTIC DISEASES 
 The phenomenon that the transmission of prion diseases 
from one species to another results in prolonged incubation 
times and survival compared to those of intraspecies 
transmission is called the “species barrier” [62]. This barrier 
is due to the variety of prion strains encompassing various 
infectious potential [63]. In natural animal populations the 
intraspecies transmission of prion diseases is much more 
efficient than an interspecies transmission [45], although 
these efficiencies can vary depending on the animal species, 
the used infectious agent and the route of infection: BSE and 
sheep Scrapie have a low intraspecies transmission effi-
ciency [64, 65] whereas CWD is rapidly transmitted in 
captive deer populations [66] (Fig. 3). Until today, mecha-
nisms underlying an intraspecies transmission remain 
unclear. But prions from one species are often less infectious 
to other species. This is thought to depend on differences in 
host prion protein sequences [67] (Fig. 4) but also may result 
from sequence differences of the 37kDa/67kDa LRP/LR 
(Fig. 5). The species barrier of an interspecies transmission 
is sometimes so strong that peripheral injection, oral trans-
mission and sometimes even an intracerebral inoculation 
with the agent causing a transmissible spongiform ence-
phalopathy (TSE) fails to develop neurodegenerative signs. 
Nevertheless, susceptible hosts show clinical signs when 
they are inoculated with brain homogenates of resistant 
species [67]. Bovine spongiform encephalopathy (BSE) is 
the only known TSE agent that was transmitted to humans 
causing the zoonotic disease vCJD [68]. Due to the fact that 
a natural infection with prions mostly occurs via oral uptake, 
 
 
Fig. (3). Intraspecies transmission efficiencies of TSEs. 
Experimental transmission of prion diseases have been performed to examine neuropathological profiles, risk factors and incidence rates. A 
long-term cohort study in cows investigating maternally-associated risk factors for BSE revealed a statistically significant risk of 10% for a 
transmission to the offspring [64]. For an intraspecies transmission of sheep scrapie, a rate of 25-40% has been calculated [66]. Chronic 











Fig. (4). Comparison of amino acid sequences of the direct and indirect PrP binding sites for LRP/LR in different species. 
PrP comprises two binding sites for LRP/LR, a direct (aa 144-179) and an indirect one (aa 53-93), that is mediated by HSPGs [3]. (a) 
Sequence alignment for the direct PrP binding site in human, cervid, ovine, bovine and porcine PrP resulted in no sequence homology, 
whereas the (b) alignment for the indirect PrP binding domain for cervid, ovine, bovine and porcine PrP, respectively, revealed 
approximately 95% sequence identity (amino acids marked in dark grey). 
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like the transmission of BSE to human, further analyses were 
performed to study the initial prion uptake. Enterocytes 
represent the major cell population in the intestinal 
epithelium and express the 37 kDa/67 kDa LRP/LR on their 
cell surface. It was hypothesized that both enterocytes and 
the LRP/LR may play a major role in oral uptake of 
infectious prions and the species barrier. Shmakov and 
colleagues demonstrated that the 67 kDa LR is expressed in 
the apical brush border of the small intestine and in the 
perinuclear region of Paneth cell secretory granules [30]. 
These findings suggest that LRP/LR might play a crucial 
role in secretory and endocytic functions in the human small 
intestine epithelium and that the consequence of the 
expression of the 37 kDa/67 kDa LRP/LR may result in an 
increased susceptibility to oral infection with prions by 
LRP/LR mediated uptake by human enterocytes [30]. 
Studies of Morel et al. showed that bovine prions were 
specifically internalized by human enterocytes (Caco-2/TC7 
cells) via the LRP/LR, whereas mouse-adapted scrapie 
prions were not endocytosed [45]. It has been demonstrated 
that BSE prion uptake was significantly reduced after 
preincubating the cells with the anti-LRP/LR antibody W3 
demonstrating that the 37 kDa/67 kDa laminin receptor is 
required for BSE prion internalization [45]. Other studies on 
oral and parenteral interspecies transmission in animals 
showed that BSE could be transmitted orally to sheep and 
goat [69], mink [70], mouse [71], but not to poultry [69]. 
Also pigs failed to be susceptible to oral BSE transmission 
[69], whereas a parenteral inoculation was successful [72] 
(Fig. 6). However, the mode of interspecies transmission of 
BSE to humans still remains unclear. Nevertheless, some 
interspecies interaction profiles of prions have already been 
elaborated employing yeast two-hybrid and conversion 
assays in vitro and transmission studies in vivo (Table 4). 
Further binding studies with prions of different species on 
bovine, porcine, cervid, ovine and human enterocytes, 
respectively, will help to unravel the species barrier in prion 
disorders and will prove whether different animal prions 
such as CWD or sheep Scrapie might cause further zoonotic 
diseases. 
4. LRP/LR AS A DRUG TARGET IN CANCER 
 Both, the 37kDa LRP and the 67kDa LR play an 
important role in cancer. The 67 kDa isoform was first 
isolated from tumor cells [5] and is termed the high affinity 
laminin receptor due to its strong binding capacity to 
laminin. Interaction of the LRP/LR with laminin, a major 
cell adhesion molecule, is crucial for the invasion of 
tumorigenic cells. There are at least two binding sites for 
laminin on LRP, one stretching from aa 205-229 and a 
second so called Peptide G sequence encompassing aa 161-
180 [6] (Fig. 1) and comprising a heparin dependent laminin 
binding site [73-75], which is equivalent to the direct PrP 
binding site. The non-integrin laminin receptor LRP/LR is 
involved in the metastatic behavior of neoplastic cells 
compromising lami-nin mediated basement membrane 
attachment, accompanied by local degradation and cell 
movement. Overexpression of the 67kDa LR has been 
detected in several cancer tissues (Table 3) including gastric 
cancer [76], colon carcinoma [77], colorectal carcinoma 
[78], cervical [79], breast [80], lung [81], ovary [82], 
pancreatic [83] and prostate cancer [84]. In addition to a 
proposed prognostic role in the metastatic tumor progression 
[85, 86], LRP/LR provides a suitable target for therapy in 
cancer. In a murine model it has been demonstrated that 
human fibrosarcoma cells pretreated with an anti-LRP 













Fig. (5). Comparison of amino acid sequences of the direct and indirect LRP/LR binding sites for PrP in different species. 
Binding of LRP/LR to PrP occurs via a direct binding site located between aa 161-179 and an indirect HSPG-dependent domain 
encompassing aa 180-295 [3]. (a) Sequence alignment of the direct LRP/LR binding site for PrP resulted in complete identical sequences for 
the human, ovine, bovine and porcine proteins. (b) Human, ovine, bovine and porcine sequences, respectively, of the indirect LRP/LR 
binding domain showed approximately 90% homology (amino acids marked in dark grey). 














Fig. (6). Oral and parenteral interspecies transmission of BSE. 
Obviously, a transmission of BSE to humans can not be tested due 
to ethical reasons. Oral transmission of the BSE agent (light gray) 
has been performed succesfully to sheep and goats [97], minks [70], 
mice [71] and cows [98], respectively. However, several 
experiments demonstrated the existence of a species barrier for the 
oral transmission of TSEs (crossed light grey arrows), e.g. in elk 
and deer, pigs [99] and poultry [69], respectively, and parenteral 
transmission (= circumvention of the intestinal tract, crossed dark 
grey arrows) to elk. Interestingly, in pigs, a parenteral BSE 
transmission (dark grey) has been reported to be succesful [100]. 
Furthermore, the BSE agent has been effectively parenteral 
transmitted to cattle [98], sheep and goats [97], minks [Bradley, 
Paris Symposium, 1996] and deer [101] (dark grey arrows). 
 
Table 3. Expression of the 67kDa LR has been Reported in 
Human Tumors 
Human tumors with LR expression Reference 
Colorectal carcinoma [78] 
Colon cancer  [112] 
Cervical preneoplastic and neoplastic squamous 
epithelial lesions 
[79] 
Gastric adenocarcinoma  [113] 
Breast carcinoma   [80, 114] 
Acute myeloid leukemia (AML) [115] 
Human laryngeal sqamous cell carcinoma [116] 
Human small cell lung cancer [117] 
Prostate cancer [84] 
Ovarian carcinoma [82] 
Uterine adenocarcinoma  [118] 
 
injected with untreated cells [87]. Furthermore a suppressed 
LRP expression was followed by a reduced lung cancer cell 
proliferation and in vivo tumor formation [88]. 
 Many tools targeting the LRP/LR for prion disease 
therapy [89], are also suitable for a tumor intervening 
therapy. Blocking or downregulating LRP/LR, significantly 
reduced the invasive potential of tumorigenic human 
fibrosarcoma cells (HT1080) [50]. Anti-LRP/LR scFv 
antibodies, the above mentionend full length format IgG, as 
well as heparan mimetics and pentosan polysulfate 
efficiently hamper the invasion through the perturbance of 
the laminin-LRP interaction on the cell surface [50]. These 
data suggest that tools targeting LRP/LR might represent 
effective alternative instruments to interfere with metastatic 
cancer. Very recently, a critical role of LRP/LR for the 
maintainance of cell viability has been reported [20]. The 
fact that neoplastic cells such as HT1080 reveal an increased 
LRP/LR level compared to non-tumorigenic cells [50] 
together with the finding that LRP/LR prevents apoptotic 
processes [20] suggests that the receptor has multiple effects 
in cancer development by supporting metastasis and 
inhibiting apoptosis. 
5. ROLE OF LRP/LR IN OTHER NEURODE-
GENERATIVE AND INFECTIOUS DISEASES 
5.1. Alzheimer’s Disease (AD) 
 Alzheimer´s and prion diseases belong to the group of 
fatal neurological disorders. Both have in common to form 
amyloid plaques on neuronal tissues. In the case of 
Alzheimer´s disease (AD) the cleavage of the amyloid ? 
precursor protein (APP) is thought to be the crucial process 
causing AD by producing the A?-peptide (A?) [90]. In the 
non-amyloidogenic pathway APP is cleaved by the ?- and ?-
secretase and the emerging soluble peptides are shedded into 
the extracellular matrix (Fig. 7). However, if the proteolytic 
processing of APP is performed by ?- and ?-secretase, the 
emerging ?-peptide (A?) which is secreted into the 
extracellular matrix, accumulates in amyloid plaques on 
neurons, accompanied by neurotoxic effects and neurode-
generation. Tau-fibres may additionally contribute to the 
development of the Alzheimer disease phenotype [91]. 
 In prion diseases, misfolding of cellular prion protein 
(PrP
c
) to a proteinase K resistant and infectious isoform 
PrP
Sc
 is thought to be the causative pathogenic mechanism of 
TSEs. PrP
c
 passes through the secretory pathway and is then 
anchored to the cell surface by a glycosyl phosphatidyl 
inositol (GPI) anchor. 
 It has been shown that cellular PrP has a regulatory effect 
on the ?-secretase cleavage of APP [92]. Overexpression of 
PrP
c
 inhibited ?-secretase cleavage and reduced A? 
formation in neuronal cells [92]. Vice versa downregulation 
of PrP
c
 by RNAi leads to the secretion of increased amounts 
of A? into the cell culture medium [92]. Additionally, PrP is 
suggested to inhibit ?-secretase (BACE1, ?-site APP clea-
ving enzyme) activity involving interaction with glucosa-
minoglycanes [92].  
 The 37kDa/67kDa LRP/LR has been shown to act as a 
receptor for both, PrP
C
 [2] and the pathogenic isoform PrP
Sc
 
[29, 45]. LRP/LR interacts with PrP via an indirect binding 
domain depending on the presence of heparan sulfate 
proteoglycans (HSPGs) [29] which belong to the group of 
GAGs. LRP/LR and APP share the same subcellular locali- 
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Table 4. Comparison of Interspecies Interactions in the Yeast Two-Hybrid System with Interconversion Studies by In Vitro 
Conversion and Transmission in Transgenic and Non-Transgenic Animals 
PrP species PrP species 
Interspecies interactions by 
yeast two-hybrid system 






transmission in animals 
Human Cattle + + [119]  + [68, 120]  + [121-123] 
Sheep Cattle + + [124]  + [125, 126]  + [127,128] 
Sheep Human + + [119]  + [125]  n.d. 
Hamster Human - -  n.d. Via guinea pigs [129] 
Hamster Cattle - - [124]  n.d. - [69] 
Cervid Cattle n.d. n.d.  - [130] n.d. 
Cervid Human n.d. n.d.  - [130,131] n.d. 
Cervid Sheep n.d. n.d.  + [131] n.d. 
Mouse Human n.d. + [132]  - [133] n.d. 
Mouse  Sheep n.d. n.d.  + [133] n.d. 
Mouse Hamster n.d. n.d.  + [133] n.d. 
“+” : Interaction in described system 
“- “ : No interaction in described system 


















Fig. (7). Overview of the non-amyloidogenic and amyloidogenic APP cleavage pathway. 
(a) In the non-amyloidogenic pathway, APP (Amyloid ? precursor protein) is proteolytically cleaved by the ?-secretase, member of the 
ADAM (a disintegrin and metalloprotease domain) family. A soluble fragment (sAPP?) is secreted into the extracellular space and the C-
terminal domain stays membrane-bound. Afterwards the ?-secretase cleaves within membrane-bound C-terminus and releases a soluble 
peptide (p3) of approximately 3kDa. The ?-secretase minimally consists of 4 individual proteins: the presenilins (aspartyl proteases) form the 
catalytic subunit, nicastrin, APH-1 (anterior pharynx-defective 1) and PEN-2 (presenilin enhancer). (b) In the amyloidogenic pathway, APP is 
first cleaved by ?-secretase (BACE1, ?-site APP cleaving enzyme), releasing a soluble fragment (sAPP?) into the extracellular space, 
followed by ?-secretase cleavage. Thereby, the amyloid ? peptide (A?), which is the primary constituent of Alzheimer’s Disease (AD), is 
shed off the cell surface and aggregates in the brain of AD patients. 
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zation on the cell surface. Therefore, it is conceivable that 
LRP/LR might be involved in secretase mediated cleavage of 
App and shedding of sAPP?, sAPP? and the ?-peptide. 
5.2. Viral Diseases 
 As an initial step in viral diseases, most viruses enter the 
host cell by receptor-mediated endocytosis. Several protein 
receptors have been identified as initial virus attachment 
receptors including human immunodeficiency virus (HIV) 
which use the chemokine co-receptors CCR5 and CXCR4 in 
addition to the CD4 receptor [93] and the Epstein-Barr virus 
that is associated with infectious mononucleosis and the 
development of cancer, respectively, and use the comple-
ment receptor CR2 [94]. For alphaviruses, e.g. Sindbis 
Virus, the high-affinity laminin receptor has been described 
as major receptor in mammalian cells [19] (Tab. 1). Hamster 
cells, that overexpress the laminin receptor at the cell surface 
were more susceptible to a Sindbis virus infection compared 
to cells transfected with the antisense gene. Moreover, it has 
been demonstrated that the 67kDa laminin receptor also 
functions as the Sindbis virus entry receptor in mosquitos 
[19]. In addition, the 37kDa/67kDa laminin receptor has 
been identified as a receptor for (i) dengue virus, which is 
the causative agent of dengue fever and dengue hemorrhagic 
fever, in human liver cells [95], porcine kidney cells [18] and 
mosquito cells [96], respectively, and (ii) for several AAV 
subtypes [16] (Tab. 1). Thus, the identification of the 37kDa/ 
67kDa LRP/LR as an initial entry receptor for mosquito-
borne viral diseases opened up new vistas to establish a 
specific receptor-based antiviral prophylaxis and/or therapy. 
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PrP27-30) = Prion protein (cellular form, scrapie 
form, protease-resistant core) 
GPI = Glycosylphosphatidylinositol 
TSE = Transmissible Spongiform 
Encephalopathy 
CJD, vCJD = Creutzfeldt-Jakob Disease, variant 
Creutzfeldt-Jakob Disease 
BSE = Bovine Spongiform Encephalopathy 
CWD = Chronic Wasting Disease 
HSPG = Heparan sulfate proteoglycan 
GAG = Glycosaminoglycan 
PPS = Pentosan polysulfate 
siRNA = Small interfering ribonucleic acid 
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fragment of APP) 
FDA = U.S. Food and Drug Administration 
AAV = Adeno-Associated Virus 
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2The 37kDa/67kDa laminin receptor (LRP/LR) was identified as a cell surface receptor for 
prion proteins. The laminin receptor mutant LRP102-295::FLAG interfered with PrPSc
propagation in murine neuronal cells presumably acting as a decoy in a trans-dominant 
negative fashion by trapping PrP molecules in the ECM. Here, we generated hemizygous 
transgenic mice expressing LRP102-295::FLAG in the brain. Scrapie-infected transgenic 
mice exhibit a significantly prolonged incubation time in comparison to scrapie-infected 
wild-type mice (FVB). At the terminal stage, transgenic mice revealed significantly 
reduced Proteinase K-resistant PrP levels by 71% compared to wild-type mice. Our 
results recommend the laminin receptor decoy mutant as an alternative therapeutic tool 
for treatment of  transmissible spongiform encephalopathies.
3Introduction
Prion diseases are neurodegenerative disorders occurring in mammals, naturally in many 
ruminants (scrapie, BSE), deer (CWD) and mink (TME), as well as in humans (CJD, FFI, 
GSS)1; 2; 3 and are characterized by the accumulation of an abnormal, partially Proteinase 
K-resistant isoform (PrPres) of the cellular prion protein (PrPc). The infectious isoform of 
the prion protein (PrPSc) tends to aggregate in brains of affected humans or animals4. All 
prion diseases show long incubation periods but are typically rapidly progressive and 
emerge in the CNS with neuropathological changes including spongiosis, astrogliosis and 
neuronal loss5.
The 37kDa/67kDa laminin receptor (LRP/LR) was identified as the cell surface receptor 
for cellular PrP6; 7 and for infectious prions8. Bovine prions are endocytosed in a LRP/LR 
dependent manner by human enterocytes9 confirming the importance of LRP/LR by the 
oral uptake of prions.
Thereupon, several therapeutic approaches regarding transmissible spongiform 
encephalopathies (TSEs) targeting LRP/LR have been developed (for review:10; 11; 12; 13
including (i) anti-LRP/LR antibodies14; 15; 16, (ii) polysulfated glycans8, (iii) a 
transdominant-negative LRP/LR decoy mutant 17 and (iv) siRNAs directed against the 
LRP mRNA18; 19. In addition, LRP/LR acts as a receptor for several viruses and is 
implicated in a wide variety of biological processes including neuronal cell adhesion, 
differentiation, migration and neurite outgrowth as well as cell survival20 and tumor 
metastasis formation (for review:12), respectively. Recently, it has been demonstrated that 
blocking or downregulating the 37kDa/67kDa LRP/LR hampered the invasion of 
tumorigenic cells in vitro21.
4LRP/LR is a multifunctional protein and is expressed within the cytoplasm, the nucleus 
and the plasma membrane, respectively (for review:11; 12), and several isoforms of 
LRP/LR are present in mouse brain22 with the 67kDa LR as the major receptor form 23. In 
contrast, LRP levels are increased in spinal cord microglia after activation by peripheral 
injury or traumatic lesion24. 
Recently, we demonstrated that LRP/LR is required for the prion propagation in scrapie-
infected neuronal cells18 and showed that secretion of the LRP102-295::FLAG mutant, 
which represents solely the extracellular domain of LRP/LR, reduced PrPSc accumulation 
in scrapie-infected mouse neuroblastoma cells17. Moreover, the LRP102-295::FLAG 
mutant reduced the binding of PrP27-30 to cells, indicating that the laminin receptor 
mutant may act in a trans-dominant negative manner as a decoy by trapping PrPSc
molecules17. Here we report the generation of hemizygous transgenic mice expressing the 
LRP mutant in the brain under the control of the rat neuron-specific enolase (NSE) 
promoter to investigate the decoy effect in vivo. Assuming that the NSE promoter-
containing construct is more efficient in various neuronal cell types than in non-neuronal 
tissues25 we concentrated on the analysis of the central nervous system (CNS). 
Previously, transgenic mice expressing trans-dominant negative mutants of PrP (Q167R 
or Q218K) have been investigated for their therapeutic potential in prion diseases and 
showed a strong effect on the reduction of PrPSc formation in vivo26. Furthermore, 
lentiviral gene transfer to deliver transdominant negative PrP mutant virions into the 
brains of scrapie-infected mice by microinjection resulted in a prolongation of survival27. 
These studies encouraged us to use the trans-dominant negative LRP102-295::FLAG 
5mutant of the prion protein receptor LRP/LR17 as a therapeutic approach for treatment of 
prion disorders in vivo.
Results
Generation of transgenic mice  
Transgenic mice were generated by microinjection of DNA into the pronuclei of 
fertilized oocytes (FVB) following transfer of the zygotes into pseudopregnant recipient 
mice. Subsequently, potential founders were genotyped by PCR to confirm the presence 
of the transgene. The plasmid, which was microinjected into the pronuclei, served as 
positive control for the correct fragment size of 711bp. The founder animal showed a 
specific single band at the correct fragment size in comparison to the wild-type mouse, 
which matched in age and showed no PCR product (Fig. 1a). A hemizygous mouse line 
TgN(NSE_LRP102-295::FLAG) was established by mating the founder animal with 
wild-type (FVB) mice. The offspring were routinely screened for the integration of the 
pCIneoNSE_LRP102-295FLAG construct by PCR analysis, followed by 1% agarose-gel 
electrophoresis. The genomic DNAs of all littermates of the F3-generation show a 
distinct band of the size of 711bp (Fig. 1b), verified by comparison with the PCR product 
of the plasmid pCIneoNSE_LRP102-295FLAG, which was used for microinjection. The 
genomic DNAs from mice of the F3-generation from another litter, previously genotyped 
as transgenic and non-transgenic (non-tg), respectively, served as positive and negative 
control animals, respectively (Fig. 1b). A control sample without DNA (H2O) was 
performed to exclude any contamination. The genotyped littermates (F3) were the 
offsprings a transgenic mouse of the F2-generation homozygous for NSE_LRP102-
6295FLAG (determined by back-crossing with wild-type mice) and a wild-type mouse and 
are consequently hemizygous (+/-) for the transgene.
Transgenic mice were visually compared with wild-type mice for variations in body size, 
body weight, movement and  coordination, respectively, and showed no visible 
phenotype. 
The laminin receptor mutant LRP102-295::FLAG is expressed in the brains of 
transgenic mice
Initially, the expression pattern of the LRP102-295::FLAG mutant was analyzed in brain 
and spleen samples from non-infected transgenic (+/-) mice of the F3-generation and age 
matched wild-type (FVB) mice (Fig. 2a). Brains and spleens were homogenized and 
subjected to 12% SDS-PAGE followed by Western blot. The mutant LRP102-
295::FLAG was detected with an antibody directed against the FLAG-tag, showing a 
distinct band at approx. 32 kDa17. The analysis revealed that the laminin receptor mutant 
LRP102-295::FLAG is expressed in the brains of transgenic mice, whereas no expression 
was detected in neither splenic tissue of transgenic mice nor in brain and spleen of non-
transgenic littermates. These results verify that the NSE promotor facilitates the 
expression of the transgene in neuronal tissues but not in the periphery of transgenic 
mice. 
To assess the ratio of the dominant negative LRP-mutant and endogenously expressed 
LRP, brain homogenates of transgenic (+/-) mice of the F3-generation and wild-type 
mice (FVB) were analyzed by Western Blotting employing the IgG1 iS18 antibody 
directed against the C-terminus of LRP21. Endogenous 37kDa LRP and LRP102-
7295::FLAG (approx. 32 kDa17) was detected in the brain of transgenic mice, whereas 
only the 37 kDa form was detected in wild-type mice (Fig. 2b). Densitometric analysis of 
the western blot data revealed no significant differences regarding the endogenous LRP 
levels in transgenic and wild-type mice (Fig. 2c). In the brain of transgenic mice, the ratio 
of LRP102-295::FLAG and endogenous LRP was approx. 1 to 1.8.
The cellular PrP level of brain and spleen remains unaltered in transgenic LRP102-
295::FLAG expressing mice
The cellular PrP levels in brain and spleen homogenates of uninfected hemizygous (+/-) 
transgenic mice of the F3-generation and wild-type mice (FVB) were analyzed to 
investigate whether the laminin receptor mutant might influence PrPc levels. 
Densitometric quantification (Fig. 3b) of western blot data (Fig. 3a) revealed no 
significant alteration of PrPc expression levels in the brain and spleen of transgenic mice 
(set to 100%) in comparison to wild-type mice (95% and 82%, respectively, p-value > 
0.05, student´s t-test). Thus, hyperexpression of the laminin receptor decoy mutant in the 
brain of transgenic mice did not influence cellular PrP expression levels, neither in the 
brain nor in splenic tissue. Statistical evaluations revealed that the levels of neither the 
diglycosylated nor the non-glycosylated form of PrPc are significantly altered in the brain 
of transgenic compared to wild-type mice (Fig. 3a).
Scrapie-infected transgenic mice show a significantly prolonged incubation time and 
reveal a significantly reduced PrPres level in the brain at the terminal stage
8To investigate whether expression of the laminin receptor decoy mutant prolongs the 
incubation time of scrapie-infected mice, intracerebral (i.c.) prion inoculation studies 
with transgenic (+/-) mice of the F3-generation expressing LRP102-295::FLAG and 
wild-type mice were performed. Six weeks old transgenic mice were intracerebrally 
inoculated with the Rocky Mountain Laboratories (RML) scrapie strain. The animals 
were sacrificed at the day when two of the TSE-relevant symptoms28 were present over 
three consecutive days. This time point is defined as the terminal stage. The period from 
the day of prion inoculation until the day the mice were sacrificed is defined as 
incubation time plotted in the Kaplan-Meier curve (Fig. 4a). The incubation time of 
scrapie-infected transgenic mice expressing LRP102-295::FLAG (1533 days, p-value < 
0.05, student´s t-test, squares) was significantly prolonged in comparison to scrapie-
infected wild-type mice (1485 days, triangles) (Fig. 4a). The results in Figure 4b are 
mean values of 11 transgenic mice and 10 wild-type mice, respectively. Statistical 
evaluations of the incubation times according to the non-parametric Wilcoxon-test (p-
value = 0.01367) and the log rank-test (p-value = 0.0215) confirmed that the reductions 
of the incubation times of scrapie-infected transgenic mice, hyper-expressing the 
LRP102-295::FLAG mutant, compared to wild-type mice are significant.
Brain homogenates of mice at the terminal stage of the disease were digested with 
Proteinase K (PK) and subjected to SDS-PAGE followed by Western blotting. The brains 
of scrapie-infected transgenic mice revealed a significant reduction of PK-resistant PrPres 
content by 71% (p-value < 0.05, student´s t-test) in comparison to scrapie-infected wild-
type mice (average of eleven transgenic and six wild-type mice, analyzed three times by 
imunoblotting) (Fig. 5a, 5b). Additionally, total PrP-levels (without PK-digestion) of the 
9brains of scrapie-infected mice were assessed by immunoblotting (Fig. 5c) and 
densitometric quantification, revealing no difference between the brains of transgenic (set 
to 100%) and wild-type mice (99%, p-value > 0.05, student´s t-test) (Fig. 5d).
Discussion
Despite numerous attempts to prevent, treat or cure prion diseases, TSEs are still 
incurable. Medications are normally associated with side effects to a grater or lesser 
extent. Thus, great efforts have been made to develop other strategies e.g. targeting prion 
protein expression via RNA interference technology29 or generation of transdominant 
negative PrP mutants26 to reduce PrPSc formation in vivo. Here, we describe the 
successful generation of transgenic mice expressing a transdominant negative laminin 
receptor mutant LRP102-295::FLAG. Encompassing the extracellular domain only, the 
LRP mutant is secreted into the extracellular matrix where it traps PrPSc molecules, 
preventing them from binding and internalization17. To generate transgenic mice 
expressing LRP102-295::FLAG, the encoding vector was microinjected into pronuclei of 
mouse zygotes. Injection before the first doubling of the chromosomes is necessary to 
avoid mosaic expression of the transgene. Since fundamental prion propagation is 
thought to occur in the CNS, expression of the laminin receptor decoy mutant in the brain 
was aimed with the NSE-promoter. Indeed, LRP102-295::FLAG expression was 
achieved in the brain of hemizygous transgenic (+/-) mice, but not in the spleen, an organ 
of the lymphoreticular system (Fig. 2a). The ratio of LRP102-295::FLAG and 
endogenous LRP expression in hemizygous transgenic mice was calculated with approx. 
1 to 1.8 (Fig. 2b and c). Homozygous transgenic mice might therefore express equal 
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amounts of the LRP-mutant and endogenous LRP, which might result in an increased 
decoy effect.
To further characterize the transgenic mice of the F3-generation, PrPc levels in the brains 
and spleens were investigated and western blot data were quantified by densitometric 
analysis. Transgenic mice show no siginificant alterations in the PrPc expression levels 
neither in the brain nor in splenic tissue in comparison to wild-type mice, suggesting that 
the expression of the LRP102-295::FLAG mutant does not influence PrPc levels. The fact 
that the levels of neither the diglycosylated nor the non-glycosylated form of PrPc are 
significantly altered in the brain of transgenic compared to wild-type mice suggests that 
LRP102-295::FLAG is not significantly impeding glycosylation and/or secretion of PrP.
To analyze the influence of laminin receptor mutant expression on disease progression in 
vivo, heterozygous transgenic mice (+/-) of the F3-generation, genotyped by PCR and 
proven to express LRP102-295::FLAG in  the brain, were intracerebrally inoculated with 
the RML scrapie strain and monitored for TSE relevant symptoms28. The incubation time 
of scrapie-infected hemizygous transgenic mice (+/-) was slightly but significantly 
prolonged (1533 days, p-value < 0.05) in comparison to scrapie-infected wild-type 
(FVB) mice (1485 days).
Transgenic mice expressing LRP102-295::FLAG revealed a significant reduction of the 
PK-resistant PrP (PrPres) level in the brain by 71% compared to wild-type mice at the 
terminal stage (the time point mice were sacrificed when two of the TSE-relevant 
symptoms28 appeared over three consecutive days).
The analysis of the total PrP content of brain-homogenates of scrapie-infected transgenic 
and wild-type mice without PK-digestion revealed no difference between the PrP-levels. 
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Assuming that only PK-digestion of PrPSc results in formation of PrPres, one might 
reason that PrPres levels after PK-digestion also represent PrPSc levels. However, one 
would expect that total PrP levels in the brains of scrapie-infected transgenic mice would 
be decreased in correlation to decreased PrPres. However, the fact that PrPc levels in 
healthy mice and total PrP levels in scrapie infected mice remain unaltered upon 
transgenicity, may suggest that PK-resistance of PrPSc might be decreased in transgenic 
mice by a so far unknown mechanism. To definitely compare PrPSc levels of scrapie 
infected transgenic and wild-type mice, however, a PrPSc-specific antibody is required.
Thus, expression of the LRP102-295::FLAG mutant in the brain of transgenic animals 
has a considerable effect on the reduction of the PrPres load in the terminal stage, but 
only a slight effect on the prolongation of the incubation time (5 days) in comparison to 
wild-type mice, suggesting that the PrPSc load does not necessarily correlate with disease 
progression or infectivity. Lasmezas and colleagues demonstrated that mice, infected 
with brain homogenates from BSE-infected cattle, reveal disease progression without 
depositing proteinase K-resistant PrP (PrPres)30. Furthermore, a rapid TSE transmission 
has been observed in mice, despite extremely low levels of disease-associated PrP31. 
Recently, high titers of TSE infectivity were associated with minimal levels of PrPSc in 
the brains of animals showing clinical and vacuolar signs of TSE32. Thus, to predict 
incubation times or life spans in vivo in TSEs, further analyses are necessary to elucidate 
the correlation of infectivity, deposition of disease-associated PrP, disease progression 
and other hallmarks of TSEs.
Our previous  studies revealed that scrapie-infected rodents showed increased LRP levels 
in the brain in comparison to non-infected rodents33, suggesting that increased 
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endogenous laminin receptor levels in the transgenic LRP102-295::FLAG expressing 
mice might compete with the secreted LRP102-295::FLAG for PrPSc binding. Increased 
LRP levels on the cell surface might reduce the decoy effect of the secreted mutant, 
trapping less infectious PrP molecules in the ECM, which might explain the only slight 
increase in incubation times of scrapie-infected transgenic LRP102-295::FLAG 
expressing mice. In contrast, the reduction of the PrPres levels in the brain of the 
transgenic mice at the terminal stage is considerable and accounts for a strong trapping 
effect, which might be even enforced in homozygous transgenic mice expressing 
LRP102-295::FLAG from both alleles. Our attempts, however, to establish a 
homozygous LRP102-295::FLAG expressing mouse line failed due to the infertility of 
homozygous transgenic mice (determined by back-crossing experiments), suggesting that 
expression of the LRP102-295::FLAG mutant from both alleles might lead to infertility. 
Beside the deficiency in reproduction, the transgenic mice showed non phenotypic 
alterations compared to wild-type mice and were clinically and physiologically normal.
In conclusion, the expression of a LRP decoy mutant in the brain, resulting in a 
significantly reduced PrPres level in the terminal stage, concomitant with a significant 
prolonged incubation time, displays an alternative promising approach in TSE therapy.
Materials and Methods
Plasmid generation and microinjection
NheI and NotI restriction sites were used to subclone the sequence encoding for LRP102-
295::FLAG17 into the pCIneoNSE-asLRP plasmid25 to generate the vector 
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pCIneoNSE_LRP102-295FLAG. The correctness of the plasmid sequence was verified 
by dideoxy sequencing. The vector pCIneoNSE_LRP102-295FLAG was linearized by 
digestion with the restriction enzymes BglII and BamHI (NEB), purified by gel extraction 
(Genomed) followed by microinjection into pronuclei of mouse zygotes (FVB) and 
transferred into oviducts of female recipient mice (NMRI). The offspring were routinely 
screened by PCR. 
Genotyping of transgenic mice by polymerase chain reaction (PCR) analysis
Genomic DNA of mice was extracted from mouse tail tips using a Tissue DNA Mini Kit 
(PeqLab) according to the manufacturer`s instructions. PCR reaction of the genomic 
DNA was performed employing recombinant Taq Polymerase Reaction Kit (Invitrogen) 
and PCR products were analyzed by 1% agarose gel electrophoresis containing GelStar
Nucleic Acid Gel Stain (Lonza). The primers used for DNA amplification are directed 
against the backbone sequence of pCIneoNSE_LRP102-295FLAG, directly before and 
after the sequence encoding for LRP102-295FLAG (primer sequence forward: 5´ TCA 
ATT ACA GCT CTT AAG GCT A 3´; primer sequence backward: 5` TTA TCA TGT 
CTG CTC GAA GC 3`). As positive control to verify the correct fragment size of the 
PCR products of the genomic DNA, the plasmid pCIneoNSE_LRP102-295FLAG was 
employed. Genomic DNAs of tg and non-tg mice, respectively, served as positive and 
negative controls, respectively. A DNA-free sample verified a contamination-free PCR 
analysis.
Analysis of protein expression
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To analyze the expression of LRP102-295::FLAG protein in the brain and spleen, organ 
homogenates from transgenic mice of the F3-generation were prepared and 100µg of 
total protein amount was subjected to 12% SDS-PAGE followed by blotting onto a 
polyvinylidenedifluoride (PVDF) membrane (Amersham). Membranes were blocked 
with 20% horse serum in PBS/0.2% Tween20 and probed with anti-FLAG M2 antibody 
(1:5000, Sigma) and anti-mouse IgG POD (1:5000, Sigma), stripped and reprobed with 
anti--actin (1:5000, Sigma) and anti-mouse IgG POD (1:5000, Sigma). For PrPres 
detection 200µg of total protein amount of each brain homogenate were adjusted in 
volume, digested with 20µg/ml PK for 30 minutes at 37°C, precipitated in 100% 
methanol and subjected to 12% SDS-PAGE. After blotting and blocking as described 
above the membranes were probed with 4H11 (1:1000, kindly provided by H. Schätzl) 
and anti-mouse IgG POD (1:5000, Sigma). Directly before PK-digestion 10µg of each 
sample were separated and analyzed for -actin content as loading control as described 
above. Blots were developed using an enhanced chemiluminescence system (Perkin 
Elmer) and exposed on chemiluminescence films (RP New, CEA). Stripping of the 
membranes was performed for 30 minutes using stripping buffer (100 mM glycine, 1% 
SDS, 0.1% Nonidet P40; pH 2.2). For total PrP detection in scrapie-infected mice and for 
PrPc detection in non-infected mice 100µg of total protein amount were treated as 
described above in the absence of PK-digestion. For endogenous LRP and LRP102-
295::FLAG detection 100µg of total protein amount were analyzed by 12% SDS-PAGE, 
followed by incubation with the LRP/LR-specific antibody IgG1 iS18 21 (1:10000) and 
the corresponding anti-human IgG POD (1:10000, Jackson Immunoresearch). After 
stripping, the membrane was reprobed for -actin detection.
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PrPSc inoculation of mice and monitoring
Six weeks old hemizygous transgenic mice expressing LRP102-295::FLAG (11 animals) 
and wild-type mice (FVB, 10 animals), respectively, were narcotized (ether inhalation) 
followed by intracerebral inoculation with 30µl of a 1% RML brain homogenate. Mice 
were monitored for the appearance of TSE-relevant symptoms 28 and the animals were 
sacrificed at the day they reveal two TSE-relevant symptoms over a period of three 
consecutive days.
Statistical analyses
Statistical analysis were performed employing a Student’s t test with two tailed 
distribution and two-sample unequal variance. For the statistical evaluation of the 
incubation times, the non-parametric Wilcoxon-test and the log rank-test were performed 
additionally.
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Fig. 1. (a) PCR analysis of genomic DNA derived from a founder animal 
(TgN(NSE_LRP102-295::FLAG)3) and an age-matched wild-type mouse in comparison 
with the plasmid pCIneoNSE_LRP102-295FLAG. A 711bp DNA fragment was 
visualized by 1% agarose gel electrophoresis. Fragment size markers in basepairs (bp) are 
indicated on the left. (b) PCR analysis of genomic DNA of  mice of the F3-generation 
derived from the founder animal (TgN(NSE_LRP102-295::FLAG)3)  (Fig. 1a). The 
vector pCIneoNSE_LRP102-295FLAG served as positive control, genomic DNAs of tg 
mice of the F2-generation and of non-tg mice from another litter of the F3-generation, 
respectively, served as positive and negative controls, respectively. A DNA-free sample 
(H2O) was used as a control. Fragment size markers in basepairs (bp) are indicated on the 
right.
Fig. 2. Transgenic hemizygous (+/-) mice of the F3 generation express LRP102-
295::FLAG in the brain. (a) Representative western blot analysis of brain and spleen 
homogenates of transgenic mice of the F3-generation and wild-type (FVB) mice, 
matching in age. Using an anti-FLAG M2 antibody, LRP102-295::FLAG expression was 
monitored in the brain and spleen of transgenic mice and wild-type mice (upper panel). 
LRP102-295::FLAG revealed a molecular weight of approx. 32kDa17. An anti--actin 
antibody was used to verify equal amounts of loaded protein (lower panel). Molecular 
weight markers in kilodalton (kDa) are indicated on the left. (b) Representative western 
blot analysis of brain homogenates of wild-type (FVB) mice and transgenic mice of the 
F3-generation. Endogenously expressed LRP and LRP102-295::FLAG was detected 
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using IgG1 iS18 directed against the C-terminus of LRP/LR 21. Wild-type mice show one 
specific band for endogenous LRP and transgenic mice reveal an additional band for 
LRP102-295::FLAG. The lower panel represents -actin detection to verify equal protein 
amounts. Molecular weight markers in kilodalton (kDa) are indicated on the left. (c) 
Densitometric analysis of western blot data of endogenous LRP and LRP102-295::FLAG 
of Fig. 2B using the NIH ImageJ software. Endogenous LRP-levels do not differ 
significantly between wild-type (117%  9%) and transgenic mice (100%  7%, p-value 
> 0.05, student´s t-test, LRP-level set to 100%). The ratio of LRP102-295::FLAG to 
endogenous LRP in the brains of transgenic mice is 1 to 1.77. Results are calculated from 
three analyses of three mice each.
Fig. 3. PrPc expression levels in brain and spleen, respectively, are similar in wild-type 
(FVB) and hemizygous transgenic mice (+/-). (a) Representative western blot analysis of
brain and spleen homogenates of transgenic mice of the F3-generation and wild-type 
(FVB) mice, matching in age. PrPc was detected using anti PrP-antibody 4H11. Equally 
loaded amounts of protein were verified by -actin detection. Molecular weight markers 
in kilodalton (kDa) are indicated on the left. (b) Densitometric analysis of western blot 
data of PrPc of Fig. 3A using the NIH ImageJ software. Splenic PrPc levels  do not differ 
significantly between transgenic (100%  11%, PrPc level set to 100%) and wild-type 
mice (82%  10%, p-value > 0.05, student´s t-test). Similarly, PrPc levels in the brains of 
transgenic (100%  46%, PrPc level set to 100%) and wild-type mice (95%  21%, p-
value > 0.05, student´s t-test) do not differ significantly. Please note that the 
unglycosylated and diglycosylated forms of PrP have been added and statistically 
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evaluated. Levels of the diglycosylated and unglycosylated forms of PrPc (analyzed 
separately) from the brain of transgenic and non-transgenic mice do not differ 
significantly.  Results are calculated from three analyses of three mice each.
Fig. 4. (a) Kaplan-Meier curve of scrapie-infected hemizygous (+/-) transgenic mice of 
the F3-generation and wild-type mice. Scrapie-infected animals were sacrificed after 
showing two TSE-relevant symptoms over a period of three days. The incubation times
of transgenic mice expressing LRP102-295::FLAG (squares), and wild-type mice 
(triangles) are displayed on the abscissa as days post scrapie inoculation. Numbers of 
mice are displayed as percentage of total mice number on the ordinate. Incubation time is 
defined as the time period from the day of RML inoculation until the animals show two 
of the TSE-relevant symptoms according to28 over a period of three consecutive days. 
This time point is defined as the terminal stage. (b) Table displaying mean values of the 
incubation time in days post scrapie inoculation (dpi). Statistical evaluations of the 
reductions of incubation time of transgenic and wild-type mice revealed p-values of 
0.027 (student´s t-test), 0.01367 (non-parametric Wilcoxon-test) and 0.0215 (log rank-
test).
Fig. 5. Western blot analysis of brain-homogenates of scrapie-infected hemizygous (+/-) 
transgenic mice of the F3 generation and wild-type mice (FVB) at the terminal stage of 
disease. (a) PK-digested brain-homogenates of scrapie-infected transgenic and wild-type 
mice were analyzed for PrPres with the anti-PrP antibody 4H11 (upper panel). Prior to 
PK-digestion 10µg of each sample was separated and analyzed for equal amounts of 
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protein employing an anti--actin antibody (lower panel). Molecular weight markers in 
kilodalton (kDa) are indicated on the left. (b) Densitometric quantification of  the western 
blot data of Fig. 4a using the NIH ImageJ software. PK-resistant PrP in the brains of 
scrapie-infected transgenic mice was significantly reduced by 71% (p-value < 0.05; 
student´s t-test) in comparison to wild-type mice (set to 100%; average of eleven 
transgenic and six wild-type mice, analyzed three times by imunoblotting) (Fig. 5a, 5b). 
(c) Brain-homogenates of scrapie-infected transgenic and wild-type mice were analyzed 
for total PrP content without PK-digestion with the anti-PrP antibody 4H11. -actin 
detection verified equal amounts of protein. Molecular weight markers in kilodalton 
(kDa) are indicated on the left. (d) Densitometric quantification of  the western blot data 
of Fig. 5C using the NIH ImageJ software. The total PrP content is equal in the brains of 
scrapie-infected transgenic (100%  6%, PrP-level set to 100%) and wild-type mice (99% 
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We examined therapeutic in vitro and in vivo approaches using lentivirus-based packaging of
small interfering RNAs (siRNAs) targeting the non-integrin laminin receptor mRNA for treatment
and prevention of prion disorders. Transfection of N2aSc+ cells with recombinant plasmids
expressing three different siRNAs, significantly reduced both the LRP (laminin receptor precursor)
and PrPSc levels by approximately 40–60%. Stereotactic intracerebral microinjection of
recombinant lentiviral vectors LVsiRNA-LRP 7 and 9 into the cortex of C57BL/6 wild-type mice
resulted in a significant reduction of the LR levels in the cortex 15 days post-injection by 62 and
82%, respectively. Intracerebral RML inoculation of C57BL/6 mice after microinjection with
recombinant lentiviral vector LVsiRNA-LRP 7 into the hippocampus resulted in a significant
reduction of both LRP and PrPSc levels by 36 and 41%, respectively, concomitant with a
significant prolongation of the pre-clinical phase. Lentiviral vectors expressing siRNAs targeting
LRP mRNA represent a novel delivery system for the treatment of transmissible spongiform
encephalopathies.
Transmissible spongiform encephalopathies (TSEs) are
fatal neurodegenerative disorders affecting animals and
humans. TSEs are characterized by the accumulation of an
‘abnormal’ pathogenic isoform (PrPSc) of the host-encoded
cellular prion protein (PrPc) in the brain of affected
individuals (Prusiner et al., 1998). According to the
‘protein-only’ hypothesis, the conversion of PrPc to PrPSc
is the pivotal event in the aetiology of TSEs (Prusiner et al.,
1990). Since prion diseases are lethal disorders, great
endeavours have been undertaken to develop an efficient
anti-prion therapy (for reviews see Ludewigs et al., 2007;
Trevitt & Collinge, 2006; Weissmann & Aguzzi, 2005).
The 37/67 kDa laminin receptor (LRP/LR) was identified
as the receptor for prions (Gauczynski et al., 2006, 2001b)
and is localized on the cell surface, in the cytoplasm and the
nucleus, respectively (for reviews see Gauczynski et al.,
2001a; Ludewigs et al., 2007; Vana et al., 2007, 2008, Zuber
et al., 2007a). Furthermore, LRP/LR colocalizes with PrP
on the cell surface (Gauczynski et al., 2001b) and in the
perinuclear compartment (Nikles et al., 2008). LRP/LR
binding to laminin, elastin and carbohydrates accounts for
its fundamental role in cell adhesion, cell movement and
growth (for review see Gauczynski et al., 2001a; Rieger et al.,
1999). LRP/LR plays an important role in the invasive and
metastatic potential of neoplastic cells (Givant-Horwitz
et al., 2005; Landowski et al., 1995) and tumour
angiogenesis (Tanaka et al., 2000) (for reviews see
Castronovo, 1993; Menard et al., 1997; Vana et al., 2008).
Blocking or downregulating LRP/LR hampers the invasive
potential of tumorigenic fibrosarcoma cells, by blocking
the laminin-1–LRP/LR interaction on the cell surface
(Zuber et al., 2008b). LRP/LR further supports mainten-
ance of nuclear structures (Kinoshita et al., 1998), supports
the translation process in the cytosol (Auth & Brawerman,
1992) and plays a critical role in maintaining cell viability
by preventing apoptosis (Susantad & Smith, 2008). On the
cell surface LRP/LR acts as a receptor for viruses such as
adeno-associated virus (AAV), dengue virus and alpha-
viruses (for reviews see Ludewigs et al., 2007; Vana et al.,
2007, 2008; Zuber et al., 2007a). However, the LRP/LR
3These authors contributed equally to this work.
A figure showing the siRNA target sequences within the murine LRP
mRNA is available with the online version of this paper.
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polymorphism seems to be enigmatic. The 37 kDa LRP is
thought to be the precursor of the 67 kDa high affinity
laminin receptor. In mammalian cells, both LRP and LR
are present in plasma membrane fractions (Gauczynski et
al., 2001a). In mouse brain both isoforms exist (Simoneau
et al., 2003). In adult rat brain the LR represents the major
isoform, whereas LRP is expressed in the post-natal central
nervous system (Baloui et al., 2004). LRP is upregulated in
spinal cord microglia after activation by a traumatic lesion
or peripheral injury (Baloui et al., 2008). The identification
of LRP/LR as the receptor for prions conducts the idea of
an alternative strategy for a TSE therapy. Application of
either LRP-specific small interfering RNAs (siRNAs), the
polyclonal anti-LRP antibody W3 (Leucht et al., 2003) as
well as a trans-dominant-negative LRP mutant (Vana &
Weiss, 2006) interferes with PrPSc propagation in vitro.
Passive immunotransfer of W3 into scrapie-infected mice
significantly reduced the peripheral PrPSc level concom-
itant with a prolongation of survival (Zuber et al., 2007b).
Delivery of single-chain (sc) Fv antibodies directed against
LRP/LR into mice by either passive immunotransfer
(Zuber et al., 2008a) or microinjection of recombinant
AAV (Zuber et al., 2008c) both resulted in a significant
reduction of peripheral PrPSc propagation.
A series of chemical compounds have been identified as
therapeutic agents efficiently interfering with PrPSc propa-
gation. Among these, only some are efficient both in vitro
and in vivo (for review see Ludewigs et al., 2007). Gene
therapy approaches evolved due to possible side effects of
drugs (e.g. toxicity, kidney damage, high blood pressure
etc.) and the limitation of either passive or active
immunization strategies.
RNA interference (RNAi) technology has been described as
one of the most powerful systems to knock-down an
endogenous gene at the post-transcriptional level (Tuschl
et al., 1999). siRNA-mediated gene transfer by lentiviral
vectors leads to a long-lasting silencing effect due to an
integration of lentiviral DNA into the genome of the target
cells (Naldini et al., 1996a).
In this study, human immunodeficiency virus (HIV)-
derived vectors that enable the expression of short hairpin
RNA (shRNA) directed against murine LRP mRNA were
generated. To examine the efficiency of siRNA target
sequences within the LRP mRNA (Supplementary Fig. S1
available in JGV Online), transfections of siRNA-encoding
plasmids (pENTR) were performed using chronically
scrapie-infected mouse neuronal cells (N2aSc+) (Fig. 1).
Cells were cultured in Dulbecco’s modified Eagle’s medium
with GlutaMax-I (Gibco) containing 10% fetal calf serum,
16 minimal essential medium non-essential amino acids,
100 U penicillin ml21, 100 mg streptomycin ml21 and
0.5 mg geneticin ml21 at 37 uC in 5% CO2. Post-
transfection (72 h), cell lysates were subjected to
Fig. 1. Influence of pENTR vectors encoding LRP-specific siRNAs on both the LRP/LR level and PrPSc propagation in scrapie-
infected neuronal cells. (a) Post-transfection (72 h) crude cell lysates of N2aSc+ cells were subjected to SDS-PAGE following
Western blotting. Cellular LRP/LR levels were detected using the single-chain anti-LRP antibody N3 (upper panel). As loading
control anti-b-actin antibody (Sigma) was used (lower panel). PrPSc detection was carried out in proteinase K-digested cell
lysates using anti-PrP SAF83 antibody (middle panel). Molecular mass markers in kilodalton (kDa) are indicated on the left. (b)
Quantitative analysis using the NIH Image software revealed reduced endogenous LRP levels by 50% for pENTR siRNA-LRP
4- (P,0.005), 47% for pENTR siRNA-LRP 7- (P,0.005) and 54% for pENTR siRNA-LRP 9- (P,0.05) transfected cells,
respectively, in comparison to pENTR siRNA-Lamin A/C-transfected cells (LRP level set to 100%). PrPSc levels were reduced
by 50% for pENTR siRNA-LRP 4- (P,0.05), 40% for pENTR siRNA-LRP 7- (P,0.05) and 43% for pENTR siRNA-LRP 9-
(P,0.05) transfected cells, respectively, in comparison to pENTR siRNA-Lamin A/C-transfected cells (PrPSc level set to
100%). The results of three individual experiments are shown and expressed as percentages of control levels±SD.
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SDS-PAGE and Western blotting. Employment of the anti-
LRP single-chain antibody N3 predominantly recognizing
the 37 kDa LRP form (Zuber et al., 2008a) and the PrP-
specific SAF83 antibody revealed that both LRP and PrPSc
levels were significantly reduced, when using pENTR
siRNA-LRP 4, 7 and 9 comparing these with the control
pENTR siRNA-Lamin A/C (Fig. 1a, upper and middle
panel). Quantitative analysis (for all quantitative analyses
the Student’s t test was used) of three independent
experiments revealed a significant reduction of the LRP
and PrPSc content by 50% with pENTR siRNA-LRP 4, by
47/40% using pENTR siRNA-LRP 7 and by 54/43% using
pENTR siRNA-LRP 9, respectively (Fig. 1b), confirming an
important role for LRP in prion propagation.
Using the Block-it Lentiviral RNAi Expression System
(Invitrogen), lentiviral RNAi vectors encoding siRNAs
directed against the LRP mRNA were generated according
to the manufacturer’s instructions. After integration of
lentiviral vector DNAs LVsiRNA-LRP 7 and 9 into the
genome of mouse neuroblastoma cells (N2a) (data not
shown), Western blot analysis of cell lysates revealed a
significant LRP/LR downregulation when comparing N2a
cells with integrated LVsiRNA-Lamin A/C DNA (data not
shown).
To investigate the effect of the LRP-specific siRNAs in vivo,
lentiviral particles [16104 transducing units (TU) per
mouse] were microinjected via a stereotactic device into the
cortex of 6-week-old anaesthetized C57BL/6 mice (four
mice per group) using a Hamilton syringe connected with
a 27-gauge needle with a flux of 1 ml min21. Cortex
samples (10% homogenates) were prepared 15 days post-
injection, followed by Western blot analysis of the LRP/LR
levels (Fig. 2a). Quantitative analysis revealed a significant
reduction of the cortical LR level by 62 and 82%,
respectively, after microinjection of lentiviral vectors
LVsiRNA-LRP 7 and 9, respectively, compared with mice
treated with LVsiRNA-Lamin A/C. Animals treated with
LVsiRNA-LRP 4 showed a not significant reduction of the
LR level by 45% (P,0.5) (Fig. 2b), suggesting a
diminished effectiveness in vivo.
Due to the significant LRP-specific silencing effects of
LVsiRNA-LRP 7 and 9, respectively, both lentiviral vectors
were selected for further studies in scrapie-infected mice.
Two weeks after microinjection of the lentiviral particles
(2.16106 TU per mouse) into the hippocampus of the
right hemisphere, mice were inoculated with 20 ml 1%
RML brain homogenate into the same brain region. To
investigate whether lentiviral particles expressing siRNAs
directed against LRP mRNA have the capacity to influence
the etiopathology of prion diseases, mice were monitored
for the occurrence of TSE-relevant symptoms (Sethi et al.,
2002) (Fig. 3a). Statistical evaluation using Kaplan–Meier
survival curves demonstrated a significant prolongation of
the pre-clinical phase in mice microinjected with
LVsiRNA-LRP 7 (145±0 days, P,0.005) and LVsiRNA-
LRP 9 (143±3 days, P,0.05), respectively, in comparison
Fig. 2. In vivo effect of lentiviral particles expressing siRNAs directed against the LRP mRNA. (a) Lentiviral particles encoding
siRNAs targeting LRP mRNA were microinjected into the cortex of C57BL/6 mice. Cortex homogenates (10%) were prepared
15 days post-injection and analysed by SDS-PAGE followed by Western blotting. Single-chain antibody scFv S18 (Zuber et
al., 2008a) was used for LR detection (upper panel) and equally loaded protein amounts were verified with the anti-b-actin
antibody (Sigma) (lower panel). Molecular mass markers in kilodalton (kDa) are indicated on the left. (b) Quantification of the
Western blot signals revealed reduced LR levels for LVsiRNA-LRP 4-, LVsiRNA-LRP 7- and LVsiRNA-LRP 9-treated animals
by 45 (P,0.5), 62 (P,0.05) and 82% (P,0.005), respectively, in comparison to siRNA Lamin A/C-treated animals (LR level
set to 100%). Experiments were performed in triplicate (four animals per group) and results were expressed as percentages of
control levels±SD. a5number of animals.
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to mice microinjected with the control LVsiRNA-Lamin A/
C (139±0 days) (Fig. 3b, c).
To analyse the protein levels, hippocampal samples were
extracted 90 days post-scrapie inoculation, digested with
20 mg proteinase K ml21 of total protein for 30 min at
37 uC following methanol precipitation and subjected to
SDS-PAGE and Western blotting. Quantification of the
data revealed a significant reduction of the endogenous
LRP and PrPSc levels by 36 and 41%, respectively, using
LVsiRNA-LRP 7 (Fig. 3d). While intracerebral microinjec-
tion of LVsiRNA-LRP 9 resulted in a significant reduction
of the LR level in the cortex of non-infected mice, the same
lentiviral vector failed to significantly reduce the LRP level
in scrapie-infected animals (Fig. 3d), although the PrPSc
level was significantly reduced by 38%. We hypothesize
Fig. 3. Analysis of scrapie-infected C57BL/6 mice after microinjection of lentiviral vectors expressing siRNAs directed against
the LRP mRNA into the hippocampus. (a) Mice were microinjected with lentiviral particles 2 weeks prior to intracerebral
inoculation with 1% RML homogenate. The first group of mice was sacrificed 90 days post-scrapie-infection to analyse the
LRP and PrP content, respectively. Remaining mice were monitored and sacrificed at the day when two of the TSE-relevant
symptoms (Sethi et al., 2002) appeared over 3 days. The pre-clinical phase (incubation time) of the disease is defined as the
time from the day of scrapie inoculation until the day where the first TSE-relevant symptom (Sethi et al., 2002) occurred,
whereas survival is the time from the day the first symptom occurred until the day where two symptoms (Sethi et al., 2002) are
manifested on 3 consecutive days. (b) Kaplan–Meier curve of 1% RML-infected mice (seven animals per group) microinjected
with LVsiRNA-LRP 7 (diamond), LVsiRNA-LRP 9 (square) and LVsiRNA-Lamin A/C (triangle), respectively. (c) Statistical
evaluation of the pre-clinical phase, survival and life span in scrapie-infected mice after injection of lentiviral vectors LVsiRNA-
LRP 7, 9 and Lamin A/C, respectively. Pre-clinical phase (incubation time) and survival are defined in (a). Life span is defined as
pre-clinical phase plus survival. Days p.i.5days post-RML inoculation. (d) Western blot data of hippocampus homogenates
(10%) from scrapie-infected mice after injection of lentiviral vectors LVsiRNA-LRP 7, 9 and Lamin A/C, respectively, 90 days
post-scrapie inoculation were quantified by NIH Image software. Antibodies scFv S18 (Zuber et al., 2008a) and SAF83 were
used for LRP and PrPSc detection, respectively. An anti-b-actin antibody (Sigma) was used for b-actin detection (control). LRP
and PrPSc levels of LVsiRNA-LRP 7 and LVsiRNA-LRP 9-treated mice were reduced by 36 (P,0.05)/41% (P,0.05) and 12
(P,0.5)/38% (P,0.05), respectively, in comparison to LVsiRNA-Lamin A/C-treated animals (LRP/PrPSc levels were set to
100%). Experiments were performed in triplicate (seven animals per group) and expressed as percentages of control
levels±SD.
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that due to the different distribution of LRP/LR isoforms in
the brain (Baloui et al., 2004), scFv S18 used for LRP/LR
detection might preferentially recognize LR in the cortex
and LRP in the hippocampus, respectively. Furthermore, it
has been demonstrated that LRP levels in the brains of
scrapie-infected hamsters are increased in comparison to
uninfected animals (Rieger et al., 1997). The silencing effect
of lentiviral vectors expressing siRNAs directed against LRP
mRNA might be weakened by so far unknown mechanisms
in the cell enhancing LRP expression in response to a
scrapie infection.
In the present study, we employed a lentiviral LRP-specific
siRNA approach and demonstrated a downregulation of
LRP/LR gene expression concomitant with a decrease of
PrPSc levels in both a scrapie cell culture and animal model,
confirming an essential requirement of LRP/LR for prion
propagation (Leucht et al., 2003). In addition, in scrapie-
infected mice injected with lentiviral vectors expressing
LRP-specific siRNAs, a significant prolongation of the pre-
clinical phase has been observed.
Thus, lentiviral-mediated siRNA delivery represents a
promising therapeutic tool to specifically knock-down
disease-relevant genes. The advantage of lentiviral vectors
lies in their ability to transduce dividing cells such as
embryonic stem cells (Pfeifer et al., 2006), and non-
dividing and terminally differentiated cells such as neurons
(Blomer et al., 1997; Naldini et al., 1996b). Recently,
lentiviral gene transfer of PrP, containing dominant-
negative mutations, was performed and resulted in an
inhibition of PrPSc formation in chronically scrapie-
infected neuronal cells (Crozet et al., 2004). Furthermore,
lentivector-mediated RNAi was used to generate chimeric
mice that express lower PrP levels depending on the degree
of chimerism. In highly chimeric mice, survival was
significantly prolonged after scrapie infection (Pfeifer et
al., 2006). These data show that the application of the
RNAi technology is a highly effective therapeutic approach
against various neurological diseases.
Very recently, we developed an AAV-based gene delivery
system targeting LRP/LR by transferring anti-LRP/LR
single-chain antibody into scrapie-infected mice (Zuber et
al., 2008c). This approach resulted in a significant
reduction of peripheral PrPSc propagation without a
significant prolongation of incubation times and survival
(Zuber et al., 2008c). In contrast, the lentiviral siRNA
delivery system presented here resulted in a significant
prolongation of the pre-clinical phase in scrapie-infected
mice, pointing towards an alternative therapeutic tool for
the treatment of prion disorders.
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2Alzheimer´s disease (AD) and Creutzfeldt-Jakob disease (CJD) are neurodegenerative
diseases sharing a characteristic pathological feature. Both show the deposition of
amyloid plaques in the brains of affected individuals1. The prion protein, associated with
Creutzfeldt-Jakob disease and other transmissible spongiform encephalopathies,
regulates the formation of amyloid β, contributing to Morbus Alzheimer2. Recently, the
non-integrin 37kDa/67kDa laminin receptor (LRP/LR) was identified as a receptor for
prions3, 4. Furthermore, the amyloid β precursor protein (APP), LRP/LR and the prion
protein localize at the cell surface, where the proteolytic cleavage of APP and the
generation of amyloid β takes place. A possible influence of LRP/LR on APP processing
and amyloid β generation has not been investigated. Here we show that incubation of
human embryonic kidney cells, endogenously expressing APP and generating amyloid β
with the LRP-specific monoclonal humanized antibody IgG1 iS18 resulted in a
significant reduction of the amyloid β generation by 99%. Furthermore, levels of the β-
secretase shedding product soluble APPβ (sAPPβ) are significantly decreased upon IgG1
iS18 antibody treatment by 99% concomitant with not significantly altered APP
expression levels, implicating that LRP/LR regulates β-secretase activity by promoting
Aβ secretion. Our results reveal that LRP/LR might play a possible regulatory role in
the enzymatic cleavage process of APP, supporting amyloidogenesis. LRP/LR specific
pharmaceuticals such as the IgG1-iS18 antibody may represent new and promising
therapeutic tools for the treatment of Alzheimer´s disease.
3Alzheimer´s disease (AD) is the most common dementia and is still incurable. It is
characterized by a loss of neurons and synapses in the cerebral cortex and certain subcortical
regions, accompanied by atrophy of the affected regions5.  The brains of patients suffering
from Alzheimer´s disease show amyloid plaque deposition and neurofibrillary tangles (NFT).
The plaque deposits mainly consist of extracellularly accumulated amyloid β (Aβ), which is a
product of the proteolytic cleavage of amyloid precursor protein (APP) (for review see6). The
neurofibrillary tangles are intraneural lesions consisting of hyperphosphorylated tau protein7,
which is a microtubule stabilizing protein. An accumulation of Aβ in the extracellular matrix
(ECM) might be due to a reduced degradation of Aβ or an increased proteolytic cleavage of
APP. In the non-amyloidogenic pathway APP is cleaved by the α-secretase releasing the
soluble N-terminal ectodomain of APP (sAPPα) into the ECM, followed by γ-secretase
cleavage, which releases a small peptide (p3) into the extracellular space. The α-secretase
cleavage is most likely performed by ADAM10 (a disintegrin and metalloproteinase) and
ADAM17, although other candidates have been identified (for review see8). The α-secretase
cleavage site is located within the Aβ peptide sequence and thus, α-cleavage precludes Aβ
peptide generation. The γ-secretase is a protease complex and consists of four integral
membrane proteins (for review see9). In case of APP processing within the amyloidogenic
pathway, β-secretase cleavage releases a soluble N-terminal part of APP (sAPPβ) into the
ECM. Beta-site-APP-cleaving-enzyme (BACE-1) has been identified as the β-secretase
homologue (for review see10). β-cleavage is followed by γ-secretase cleavage, producing
predominantly Aβ isoforms Aβ1-40 and Aβ1-42. Aβ1-42 is particularly prone to precipitation
and aggregation11. The physiological function of APP is still poorly understood and remains
under investigation. It has been suggested that APP might act as a receptor or a growth factor
due to its growth factor like domain at the N-terminus12. APP has further been proposed to
4play a role in cell adhesion, migration and proliferation13 as well as cell movement
regulation14.
Recently, a regulatory effect of the cellular prion protein (PrPc) on the  β-secretase
cleavage of APP has been described2. PrPc directly interacts with the β-secretase and inhibits
its enzymatic activity, thereby preventing the generation of Aβ peptides2. The misfolded
infectious isoform of the host encoded cellular prion protein is called PrPSc and is supposed to
act as the causative agent of transmissible spongiform encephalopathies (TSE), which include
Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), Kuru and
fatal familial insomnia (FFI) in humans, bovine spongiform encephalopathy (BSE) in cattle
and scrapie in sheep. Although the function of the prion protein has to be further elucidated it
has been suggested that PrPc plays a role in e.g. copper trafficking, T-cell function and
oxidative stress homeostasis (for review see15). The 37kDa/67kDa laminin receptor (LRP/LR)
was identified as a receptor for PrPc4 and PrPSc3. LRP/LR and PrP co-localize in the
perinuclear compartent and at the cell membrane of baby hamster kidney (BHK) cells16.
LRP/LR mediates bovine prion endocytosis by human enterocytes17, suggesting an important
role of the receptor in the species barrier of prion diseases. LRP/LR represents a promising
alternative target in prion disorders (for review see18-20). The laminin receptor is involved in
the translational machinery21,22 and the maintanance of nuclear structures23. LRP/LR is a
receptor for elastin, carbohydrates and a series of viruses such as Venezuelean equine
encephalitis virus (VEE), Sindbis virus and Dengue virus, and certain AAV subtypes (for
review see19). LRP/LR is involved in cell adhesion and tumor metastasis formation24. Tools
downregulating or blocking LRP/LR such as the monoclonal antibody IgG1-iS18 impede the
two key components of metastatic tumors: invasion and adhesion25.
The finding that the cellular prion protein regulates Amyloid β secretion2, together
with the fact that LRP/LR acts as a receptor for prions3, 4, encouraged us to investigate a
possible influence of the laminin receptor on the generation of Aβ. Additionally, as integral
5membrane proteins APP and LRP/LR share the same subcellular localization with the
glycosyl-phosphatidylinositol (GPI) anchored PrPc, a direct interaction partner of LRP/LR
and the APP-processing β-secretase, suggesting a possible linkage between both regulatory
networks. We investigated the influence of the anti-LRP/LR specific antibody IgG1-iS18 on
the release of amyloid β in human embryonic kidney cells (HEK293FT), selected as the
model cell line due to endogenous expression of APP26. HEK293FT cells indeed express
moderate levels of APP (Fig. 1a, no antibody treatment) and release considerable amounts of
amyloid β into the conditioned medium (Fig.1e, no antibody treatment). Treatment of
HEK293FT cells with the LRP/LR-specific antibody IgG1-iS18 significantly reduced Aβ
levels in contrast to IgG1-HD37 directed against CD-19 on human B-lymphocytes which had
no significant effect on Aβ-levels (Fig.1e). Densitometric analysis of the amyloid β signals
revealed a significant reduction of amyloid β levels in the conditioned media of cells treated
with IgG1-iS18 by 99% (p-value<5*10-8, two-tailed t-test, n=6) in comparison to non-treated
cells (Fig. 2). APP expression levels were not significantly altered in the presence of IgG1-
iS18 (Fig.1a; Fig. 3), suggesting that decreased amyloid β levels by IgG1-iS18 are not due to
decreased APP levels. IgG1-HD37 had no significant effect on the release of amyloid β from
HEK293FT cells (Fig. 1e; Fig. 2) and no significant influence on endogenous APP and LRP
levels (Fig. 1a, b; Fig. 3). LRP levels remain unchanged upon treatment with IgG1-iS18 (Fig.
3) indicating that the significant reduction of amyloid β levels by IgG1-iS18 is not due to an
altered LRP expression level. Shedding of sAPPβ is due to the enzymatic processing of APP
by β-secretases during the amyloidogenic pathway. Thus, sAPPβ levels in the conditioned
media of HEK293FT cells were analyzed to investigate whether the reduction of Aβ levels
might be due to an impairment of the β-secretase activity. Statistical evaluations of the sAPPβ
levels in the media of IgG1-iS18 treated HEK293FT cells (Fig. 1d) revealed a significant
reduction by 99% (Fig. 4) compared to non-treated cells (p-value<0.0005, two-tailed t-test,
6n=6). The decrease of amyloid β levels (Fig. 2) correlates with the reduction of sAPPβ levels
(Fig. 4) indicating that treatment with the LRP-specific antibody IgG1-iS18 impairs β-
secretase activity and thereby prevents the release of sAPPβ.
Prion diseases in humans, such as Creutzfeldt-Jakob disease (CJD) and AD might be
connected regarding the co-existence of amyloid β plaques and PrPSc deposition or further
pathogenic and clinical similarities27, 28. A regulatory influence of prion protein levels on
amyloid β formation has been shown2, 29, although leading to contradictory results.  Most
recently, it was demonstrated that PrP antibodies prevent amyloid β-oligomer binding to PrPc
and rescue synaptic plasticity in hippocampal slices from oligomeric amyloid β suggesting
that PrPc is a mediator of amyloid β-oligomer-induced synaptic dysfunction30. The discovery
of LRP/LR as a receptor for prions might represent a link to the regulatory network of
proteins and enzymes related to amyloid β generation, especially since APP, APP processing
enzymes, PrPc and its receptor LRP/LR are all localized on the cell surface. Here, we report
on the in vitro effect of the LRP/LR specific monoclonal antibody IgG1-iS18 on the amyloid
β levels secreted from human embryonic kidney cells. Amyloid β levels in the conditioned
media of HEK293FT cells were significantly reduced by 99% after pre-incubation of the cells
with IgG1-iS18. APP and LRP levels were not altered upon IgG1-iS18 treatment, suggesting
that the significant reduction of amyloid β levels is not a consequence of reduced APP or LRP
levels. To elucidate whether the β-secretase as the direct interaction partner of PrPc2 might be
associated with the regulatory effect of LRP/LR, the sAPPβ levels of the conditioned media
of the IgG1-iS18 treated cells were analyzed. After treatment of HEK293FT cells with IgG1-
iS18, sAPPβ levels were significantly decreased by 99%, which correlates with the significant
reduction of amyloid β levels by 99%. These results indicate that LRP/LR might regulate β-
secretase activity, increasing sAPPβ shedding and amyloid β secretion. PrPc and its receptor
LRP/LR therefore encompass oppose effects within the amyloidogenic pathway: PrPc
7decreases β-secretase activity, impedes sAPPβ shedding and Aβ-production2, whereas
LRP/LR seems to have oppositional effects since the LRP/LR specific antibody IgG1-iS18
significantly reduces amyloid β and sAPPβ levels. Our results recommend the humanized
monoclonal antibody IgG1-iS18 which renders it suitable for a possible clinical applicability
in humans as a new and promising therapeutic tool for the treatment of Alzheimer’s disease.
METHODS
Human embryonic kidney (HEK293FT) cells were cultured in Dulbecco's Modified Eagle
Medium with 4.5g/l glucose (DMEM, Pan Biotech) supplemented with 10% fetal calf serum
(FCS, Gibco) and 1% PenStrep (10000U/ml Penicilline and Streptomycine, Gibco) at 37°C
and 5% CO2. The cells were plated to 30% confluency. After 24 hours, culture medium was
exchanged now containing 50µg/ml anti-LRP/LR antibody IgG1-iS18, control antibody IgG1-
HD37 or no antibody. The conditioned media and the cells were harvested 48 hours after the
medium exchange. The cells were lysed with lysis buffer (10mM Tris/HCl, pH=7.5; 100mM
NaCl; 10mM EDTA; 0.5% Nonidet P-40; 0.05% Deoxycholic acid) for 10 minutes on ice,
scraped off the plates and centrifuged for 10 minutes at 14000rpm at 4°C to remove cell
debris. Cell lysates were analyzed for APP, LRP and β-actin by a 12% sodium dodecylsulfate
polyacrylamide gelelectrophoresis (SDS-PAGE). The conditioned media were analyzed for
sAPPβ by 6% SDS-PAGE and for Aβ by 4%-16.5% Tris-tricine gelelectrophoresis. After
blotting onto a polyvinylidene difluoride (PVDF) membrane (GE Healthcare), unspecific
binding sites were blocked with 20% horse serum in phosphate buffered saline containing
0.2% Tween 20 (PBS-T 0.2%), followed by incubation with antibodies in 10% horse serum in
PBS-T 0.2%. Amyloid β and sAPPβ were detected using anti β-amyloid (1/5000, Rockland)
and anti-sAPPβ-wt (1/100, IBL), respectively. APP was detected with anti-APP Y188
(1/5000, Abcam) and LRP was detected using IgG1-iS18 (1/10000, Affimed Therapeutics).
As loading control for the cell cell lysates β-actin was detected with anti-β-actin (1/5000,
8Sigma). Blots were developed using AceGlow (PeqLab). For vizualization the membranes
were exposed on chemiluminescense films (RP New, CEA). Stripping of the membranes was
performed using stripping buffer (100 mM glycine, 1% SDS, 0.1% Nonidet P40; pH 2.2).
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Figure 1| Analysis of Aβ, sAPPβ, APP and LRP levels secreted from and in
HEK293FT cells treated with anti-LRP/LR antibody IgG1-iS18. Representative
Western blot of HEK293FT cells, endogenously expressing APP, treated with
50µg/ml IgG1-iS18, IgG1-HD37 or no antibody for 48 hours. Cell lysates were
analyzed for APP (a), LRP (b) and β-actin (c) by 12% SDS-PAGE. The conditioned
media were analyzed for sAPPβ (d) by 6% SDS-PAGE and amyloid β (e) by 4-16,5%
Tris-Tricine gelelectrophoresis. Analyses were performed twice, each in triplica.
Molecular weight markers are indicated on the left.
Figure 2| Densitometric quantification of amyloid β levels released from
HEK293FT cells after treatment with anti-LRP/LR antibody IgG1-iS18. Signals for
amyloid β (Fig. 1e) were quantified using NIH ImageJ software. The amyloid β levels
in the conditioned media of HEK293FT cells, treated with 50µg/ml IgG1-iS18, were
significantly reduced by 99% ± 0.5% s.d. in comparison to amyloid β levels from non-
treated cells (p-value<5*10-8, two-tailed t-test). All error bars represent mean and
s.d., n=6.
Figure 3| Densitometric quantification of LRP and APP levels in HEK293FT cells
treated with anti-LRP/LR antibody IgG1-iS18. Western blot data of APP and LRP
(Fig. 1a,b) were quantified using NIH ImageJ software. APP and LRP levels were not
significantly altered upon antibody treatment with IgG1-iS18 or IgG1-HD37 in
comparison to APP and LRP levels of untreated cells, respectively. All error bars
represent mean and s.d., n=6.
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Figure 4| Densitometric analysis of sAPPβ levels secreted from HEK293FT cells
after treatment with anti-LRP/LR antibody IgG1-iS18. Signals for sAPPβ (Fig. 1d)
were quantified using NIH ImageJ software. The sAPPβ levels in the conditioned
media of HEK293FT cells, treated with IgG1-iS18, were significantly reduced by 99%
± 1% s.d. in comparison to sAPPβ levels released from non-treated cells (p-
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The 37 kDa/67 kDa laminin receptor LRP/LR acts as a receptor for both PrPc and PrPSc at the cell surface. Here,
we further analyzed the subcellular localization of ﬂuorescent labeled prion protein (PrP) and laminin
receptor (LRP/LR) molecules. We show that EGFP-PrP is localized at the cell surface and in a perinuclear
compartment, respectively. In contrast, a DsRed-ΔSP-PrP mutant lacking the signal peptide is almost
exclusively found in the nucleus but does not colocalize with heterochromatin. Interestingly, LRP-DsRed
efﬁciently colocalizes with EGFP-PrP in the perinuclear compartment and LRP-ECFP partly colocalizes with
DsRed-ΔSP-PrP in the nucleus, respectively. We conclude that the interactions of PrP and LRP/LR are not
restricted to the cell surface but occur also in intracellular compartments suggesting a putative role of LRP/LR
in the trafﬁcking of PrP molecules.










The cellular prion protein PrPc is one of the most studied proteins
in eukaryotic cell biology, because it is not only the central player
in prion diseases but it unraveled how an infectious agent could
consist of protein only. The so-called protein-only hypothesis, which
was formulated by Stanley B. Prusiner in 1982 [1] is nowadays well-
grounded on recent studies [2,3]. However, it still remains an open
task to determine the function of PrPc, because Prnp knock-out mice
showed no obvious phenotype [4]. There exist a tremendous number
of postulated functions for PrPc [5–11] including copper binding,
signal transduction, neuroprotection and oxidative stress reactions.
Previously, a green ﬂuorescent protein coupled PrPc has been used
in many studies for subcellular visualization of the protein [12–16]. In
living cells, immunoﬂuorescent studies showed an equal localization
pattern compared to endogenous PrP [17]. Interestingly, a mutant
version of PrPc lacking its signal peptide translocates the protein from
the endoplasmatic reticulum to the nucleus [18]. However, the ﬁnding
cannot be explained by the presence of nuclear localization signals
within the protein sequence [18]. Since PrPc has RNA binding
properties [19], the nuclear localization of truncated PrPc may be of
physiological relevance.
The 37 kDa/67 kDa laminin receptor (LRP/LR) plays a major role
within the cellular functions of PrPc. The protein is a multifunctional
type II transmembrane protein with roles in ribosomal transcription,
cell attachment, tumor metastasis formation and functions as a
receptor for various viruses (for review: [20]). LRP/LR acts as a cell
surface receptor for PrPc [21] and for infectious prions [22,23]. Re-
cently, several approaches for prion disease therapy targeting LRP/LR
have been described (for review: [20,24,25]. These include (i)
antibodies directed against the 37 kDa/67 kDa LRP/LR [26,27], (ii)
siRNAs targeting the 37 kDa LRP mRNA [28] (Ludewigs et al., in
preparation), (iii) transdominant negative LRP/LR mutants acting as a
decoy [29] and (iv) polysulfated glycanes [22]. Blocking or down-
regulation of LRP/LR by these molecular tools reduced invasion of
tumorigenic ﬁbrosarcoma cells (HT1080) recommending these mole-
cules as alternative therapeutics for prevention of cancer metastasis
and tumor progression [30]. In the present study, we used both
ﬂuorescence-coupled PrPc and LRP/LR to visualize both proteins after
transfection in eukaryotic cells. We generated cyan ﬂuorescent LRP
(LRP-ECFP), red ﬂuorescent LRP (LRP-DsRed) and green ﬂuorescent
LRP (LRP-EGFP), respectively, as well as a red ﬂuorescent prion protein
mutant lacking its signal peptide (DsRed-ΔSP-PrP). In addition, we
used full-length prion protein coupled to the green ﬂuorescent protein
(PrP-EGFP) [17]. Here, we describe the subcellular localization of these
proteins after transient transfection in two different cell lines
employing confocal immunoﬂuorescence (IF) microscopy. We conﬁrm
that PrP-EGFP is localized in a perinuclear compartment and on the
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cell surface. Moreover, we show that DsRed-ΔSP-PrP is translocated
into the nucleus without colocalization with heterochromatin. Addi-
tionally, we observe a colocalization of LRP-DsRed and EGFP-PrP in the
perinuclear compartment and a partly colocalization of LRP-ECFP and
DsRed-ΔSP-PrP in the nucleus suggesting a potential role of PrPc in
gene regulation.
2. Material and methods
2.1. Plasmid constructions
For the generation of the plasmid pDsRed-ΔSP-PrP, the coding sequence for DsRed
was ampliﬁed from the plasmid pDsRed-Express-N1 (Clonetech) using the oligonu-
cleotides 5′-AgeI-DsRed (5′-GTCAAACCGGTCGCCACCATGGC-3′) and 3′-BglII-DsRed (5′-
GTCAAAGATCTCA GGAACAGGTGGTGGCG-3′) and subsequently inserted into the target
vector pEGFP-PrP [17] using the restriction sites AgeI and BglII. The plasmid pLRP-DsRed
was cloned by inserting the murine laminin receptor coding sequence (ampliﬁed from
pSFV1-moLRP::FLAG [22]) into the target vector pDsRed-Express-N1 (Clonetech) by use
of BamHI- and SmaI-coding oligonucleotides 5′-BamHI-LRP and 3′-SmaI-LRP (5′-GTCA-
AGGATCCGCCACCCATGTCC-3′, 5′-GTCAACCCGGGGCCACCATGTCCGGAGCC-3′). The
plasmid pLRP-EGFP was generated by insertion of the LRP cassette ampliﬁed from
pSFV1-moLRP::FLAG using the oligonucleotides 5′-XmaI-LRP (5′-GTCAACCCGGGCCAC-
CATGTCCGGAGCC-3′) and 3′-BamHI-moLRP (5′-GTCAAGGGATCCGGACCACTCAGTGGT-
GGC-3′) into the plasmid pEGFP-N3. The vector pLRP-ECFP was cloned in two steps.
First, pECFP-N1 plasmid was generated via exchange of DsRed with the ECFP cassette
ampliﬁed from pECFP-Endo vector (Clonetech) with the primers 5′-AgeI-ECFP (5′-
GTCAAACCGGTCGCCACCATGGTG-3′) and 3′-NotI-ECFP (5′-GTCCAGCGGCCGCTACTTG-
TACAGCTCGTCCATG-3′) and subsequent insertion into pDsRed-Express-N1 vector. In
the second step, the murine LRP sequence was inserted into the newly generated vector
pECFP-N1 by restriction of the pLRP-DsRed plasmid using the restriction enzymes XmaI
and AgeI. All generated plasmid sequences were veriﬁed by dideoxy sequencing.
2.2. Cell culture and transfections
Baby hamster kidney (BHK, ATCC CCL-10) and murine neuroblastoma cells (N2a,
ATCC CCL-131) were cultivated in DMEM (Invitrogen) supplemented with 10% fetal calf
serum (Invitrogen) and 1% non-essential amino acids. For calcium phosphate transfection,
cells were plated at 30% conﬂuency in 6 well plates prepared to contain one coverslip
per well and were incubated overnight to enable cell attachment. In total, 8 µg of mixed
plasmids plus 9 µl (2.5 M) calcium chloride completed to 90 µl with ultrapure water was
prepared. Next, 90 µl of sterile ﬁltered HBS buffer (sodium chloride 281 mM, HEPES
100 mM, sodium phosphate 1.5 mM, pH 7.12) was added while plasmids were vortexed
for 1 min and precipitates were added onto the cells containing 25 µM chloroquin in
DMEM. Media were changed once after 8 h and a second time after overnight
incubation. Transfection experiments were carried out in three individual experiments.
2.3. Western blot analyses
48 h after transfection, cells were detached by trypsin (0.1% in PBS) lysed in 50 µl
lysis buffer (10 mM Tris/HCl pH 7.5, 100 mMNaCl, 10 mM EDTA, 0,5% Nonidet P-40, 0,5%
Desoxycholate) and incubated on ice for 30 min. Samples were centrifuged at
14,000 rpm in an Eppifuge (Heraeus) and supernatant was mixed with SDS sample
buffer. Samples were boiled at 95 °C for 5 min and subjected to SDS polyacrylamide gel
electrophoresis using a 12% separation gel. Samples were blotted on nitrocellulose
membranes and blocked by horse serum (20% in PBS) followed by incubation with
either anti-PrP antibody SAF 32 (1:5000) [31] or anti-LRP antibody W3 (1:5000) [21].
Blots were then incubated with the secondary anti-mouse and anti-rabbit HRP
conjugated antibody (Sigma) (1:5000), respectively, following detection using Super-
Signal detection kit (Pierce).
2.4. Immune ﬂuorescence and confocal microscopy
24–48 h post transfection cells were ﬁxed using 4% paraformaldehyde for 20 min at
room temperature and were stained by 10 µg per ml DAPI for 10 min at room
temperature. After threefold PBS wash cells were embedded using confocal matrix
(MicroTechlab). The confocal analyses were carried out on a Leica DM IRE2 confocal
microscope using the Leica confocal software TCS SP2 version 2.5.
3. Results
3.1. Cloning and expression of the ﬂuorescence labeled prion protein and
the 37 kDa/67 kDa laminin receptor
The ﬂuorescent fusion proteins were generated on the basis of
pEGFP-N1 and pDsRed-N1 as well as pECFP-C1 and pDsRed-C1 vector
backbones, respectively. The insertion resulted in ﬂuorescence-coupled
variants of the mouse prion protein and the murine laminin receptor
fusion proteins (Fig.1A). The enhanced green ﬂuorescent protein (EGFP)
was placed in frame between the prion protein-derived signal peptide
[9] to obtain the EGFP-PrP fusion protein. The variant lacking the signal
peptidewas fused to theC-terminus of theDsRed sequence (DsRed-ΔSP-
PrP). In case of the laminin receptor (LRP/LR) fusion proteins, the
ﬂuorescent proteinswere fused in frame to theC-terminal end of LRP/LR
to obtain LRP-ECFP, LRP-DsRed and LRP-EGFP, respectively. The expres-
sion of the prion protein fusion protein variants EGFP-PrP and DsRed-
ΔSP-PrP in BHK cells was conﬁrmed by Western blotting showing that
both proteins were present in cell lysates (Fig. 1B, left panel, lanes 1, 2).
The EGFP-PrP was typically glycosylated showing a three band pattern
Fig. 1. Expression of the PrP fusion proteins and the 37 kDa/67 kDa laminin receptor in mammalian cells. (A) Fluorescent gene fusion constructs were generated and transiently
transfected into BHK cells to investigate the subcellular localization of PrP and LRP/LR, respectively. The cDNA for the signal peptide (SP) of murine PrPc was cloned N-terminally, the
cDNA encoding amino acids 23–254 C-terminally to EGFP and DsRed. The sequence of murine LRP was cloned N-terminally to the ECFP, DsRed and EGFP proteins, respectively. (B)
Expression of PrP derived fusion proteins was analyzed 48 h post transfection (left panel). Both EGFP-PrP (lane 1) and DsRed-DSP-PrP (lane 2) in comparison to non-transfected cells
(lane 3) were detected using the PrP-speciﬁc mAb SAF 32. Expression of LRP derived fusion proteins was analyzed in BHK cells 48 h post transfection (right panel). LRP-ECFP derived
cell lysate (lane 1) and LRP-DsRed derived cell lysate (lane 3) were compared to mock-transfected cells (lanes 2, 4, 6) using the polyclonal anti-LRP serum W3.
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between 48 kDa and 60 kDa (Fig. 1B, left panel, lane 1), whereas the
variant lacking the signal peptidewas unglycosylated (Fig.1B, left panel,
lane 2). The increased molecular weight of the PrP proteins resulted
from the EGFP fusion that has a molecular weight of approximately
35 kDa. Moreover, the speciﬁcity of the antibody stain was conﬁrmed
using non-transfected control cell lysate (Fig. 1B, left panel, lane 3).
In addition, the expression of the LRP/LR fusion proteins LRP-ECFP
(Fig. 1B, right panel, lane 1), LRP-DsRed (Fig. 1B, right panel, lane 5) and
Fig. 2. Localization of green ﬂuorescent protein coupled prion protein (EGFP-PrP) in a perinuclear compartment. (A) EGFP-PrP was examined 48 h post transfection in BHK cells using
confocal microscopy. (B) Co-staining of the nucleic laminawith a lamin B-speciﬁc antibody followed by incubationwith a secondary antibody conjugatedwith indocarbocyanine Cy3.
(C) Merge of A and B. The bar represents 4 µm.
Fig. 3. The prion protein mutant DsRed-ΔΔSP-PrP does not colocalize with heterochromatin in the nucleus. (A) N2a cells were transiently transfected with DsRed-ΔSP-PrP and
analyzed by confocal microscopy. Z sections through an individual cell were performed varying about 2.8 µm in the z plane in total (individual steps 0.2 µm). (B) The same cell was
simultaneously stained by DAPI (10 µg/ml) and analyzed for heterochromatin/DNA staining, respectively. (C) Merge of A and B. The bar represents 6 µm. (D) N2a cells were transfected
with DsRed-ΔSP-PrP and analyzed by confocal microscopy. (E) Simultaneously, the same cell was stained with DAPI (10 µg/ml) and analyzed for heterochromatin/DNA staining using
the EGFP channel for better visualization. (F) Channels were merged. The bar represents 8 µm.
337D. Nikles et al. / Biochimica et Biophysica Acta 1782 (2008) 335–340
LRP-EGFP (Fig. 1B, right panel, lane 3), respectively, has been veriﬁed
employing the polyclonal LRP antibody W3 [25,32].
3.2. EGFP-PrP accumulates in the perinuclear compartment
EGFP-PrP was transfected into BHK cells and subcellular localization
was examined 24 h post transfection by confocal ﬂuorescence mic-
roscopy. In cells expressing high levels of the transgene an accumulation
of EGFP-PrP inanendosomal compartment (Fig. 2A)whichwas localized
in closeproximity to thenucleuswas observed (Fig. 2B, C). Thisﬁnding is
supported by previous publications demonstrating that EGFP-PrP is
localized in eitherGolgi compartments or, after internalization of PrPc, in
endosomal compartments including an accumulation in the perinuclear
compartment [16,17].
3.3. DsRed-ΔSP-PrP is localized in the nucleus and does not colocalize
with heterochromatin
Themutant PrP DsRed-ΔSP-PrP lacking the signal peptide revealed
a distinct localization pattern (Fig. 2B) in neuronal cells (N2a). The
mutant PrP variant did not colocalize with EGFP-PrP (data not shown)
andwas localized in the nucleus andnot in the cytoplasm (Fig. 3 A). The
nucleic localization of PrP lacking its signal peptide has been reported
previously in a study using antibody-based ﬂuorescent-staining [18].
Here, we conﬁrm this ﬁnding by transient transfection of DsRed-ΔSP-
PrP in BHK cells (data not shown) in addition to N2a cells (Fig. 3).
However, upon co-staining of the DNA with DAPI (Fig. 3B, E) no
colocalization of red ﬂuorescent DsRed-ΔSP-PrP and the heterochro-
matin (Fig. 3C)was detected. Due to the indistinct analysis of themerge
of the blue DAPI stain and the red ﬂuorescence of DsRed-ΔSP-PrP, the
ﬁlter of the confocal microscope was changed from blue to green for
the visualization of DAPI (Fig. 3E, F). Our ﬁnding implicates that the
herein used DsRed-ΔSP-PrP does not colocalizewith heterochromatin.
3.4. The 37 kDa/67 kDa laminin receptor colocalizes with EGFP-PrP and
partly colocalizes with DsRed-ΔSP-PrP in the nucleus
Furthermore, we investigated the distribution of the 37 kDa/67 kDa
laminin receptor (LRP/LR) upon cotransfection using the different PrP
variants. Cotransfection of EGFP-PrP and LRP-DsRed resulted in a
colocalization in the perinuclear compartment and on the cell surface
(Fig. 4A). In earlier studieswe showed that PrPc and LRP/LR colocalize on
the cell surface of neuroblastoma cells [21]. In addition, LRP-ECFP also
localized in the nucleus of cotransfected DsRed-ΔSP-PrP cells. This
ﬁnding argues that upon expression of the PrP mutant, LRP/LR was
partly directed to or localized to the nucleus (Fig. 4B) and not localizing
within the perinuclear compartment. Previously, it has been shown that
LRP/LR iswidely spread through all cellular compartments including the
cytoplasm, the nucleus and the cell surface where it contributes to its
multifunctional role in cell biology [33–35]. Although a typical colo-
calizationpatternwasnot observed,we found that LRP-ECFPandDsRed-
ΔSP-PrP were partly colocalized in the nucleus (Fig. 4B).
4. Discussion
4.1. Putative role of the prion protein mutant DsRed-ΔSP-PrP in the
nucleus
The eukaryotic cell nucleus is organized within subnuclear com-
partments including the nucleic envelope, the eu- and heterochroma-
tin aswell as the nucleoli as sites of ribosomeproduction and assembly.
A variety of proteins are localized in the nucleus and are part of the
ribosomal, replication or transcription machinery and the spliceo-
some, respectively. However, a putative role of a prion protein located
in the nucleus, in case its signal peptide is genetically removed, is
highly speculative. So far, there is no evidence that PrP lacking its signal
peptide is present in the nucleus under physiological conditions.
Nevertheless, the nuclear localization of DsRed-ΔSP-PrP is astonishing.
As it was previously discussed, there is no evidence, that a nuclear
localization signal is responsible for such action [18]. Until now it is
speculative how PrP in the absence of its signal peptide targets the
nucleus. Further analyses are required to unveil this mode of action.
4.2. The 37 kDa/67 kDa laminin receptor and the prion protein colocalize
intracellularly
In the present report, we show for the ﬁrst time the intracellular
colocalization of LRP/LR with PrP. We hypothesize that the nucleic
Fig. 4. Colocalization of the 37 kDa/67 kDa laminin receptor (LRP/LR) with green ﬂuorescent protein coupled prion protein (EGFP-PrP) and in part-colocalization with the mutant
prion protein DsRed-ΔSP-PrP. (A) BHK cells were transiently cotransfected with pEGFP-PrP and pLRP-DsRed. 48 h post transfection cells were ﬁxed and the distribution of ﬂuorescent
proteins was analyzed by confocal microscopy. Green channel (left pannel), red channel (middle pannel) and merge (right pannel). (B) BHK cells were transiently cotransfected with
pDsRed-ΔSP-PrP and pLRP-ECFP. 48 h post transfection cells were ﬁxed and the distribution of ﬂuorescent proteins was analyzed by confocal microscopy. Red channel (left pannel),
blue channel (middle pannel) and merge (right pannel). The bar represents 20 µm.
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localization of themutant PrPmight be based on the passive transport
via an interaction with another protein. Such an interaction partner
might be the 37 kDa/67 kDa laminin receptor LRP/LR which has been
identiﬁed as the cell surface receptor for the cellular PrP and infectious
prions [21–23]. To investigate this possibility, we generated ﬂuores-
cent LRP variants,whichwere used for colocalization studieswith both
EGFP-PrP and DsRed-ΔSP-PrP. Our results are consistent with thewide
cellular localization pattern of LRP-EGFP including the nucleus, the
cytoplasm and the cell surface. Previously, it has been reported that
LRP/LR, which is basically identical with the ribosomal protein p40
playing an important role in the translationprocess, is transported into
the nucleus under specialized conditions [36]. It has further been
shown that LRP/LR is located inside the nucleus, beside cytoplasmic
and cell surface localization, where it binds to histones [34,35]. Further
experiments are required to enlighten the unknown mechanism by
which cytoplasmic PrP variants are targeted to the nucleus.
Since internal nuclear localization signals are not involved in
nucleic import of the prion protein lacking the signal peptide [18], an
alternative way of nuclear import may involve an adapter protein that
contains a nuclear localization signal. It has been shown that the
37 kDa LRP is directed to the cellular nucleus after addition of midkine,
a heparin binding growth factor [36,37]. According to the binding
ability of PrP to LRP [21,38], we speculate that the nuclear localization
of the PrP variant DsRed-ΔSP-PrPmight be also dependent onmidkine.
This explanation, as well as the multifunctional role of LRP/LR in the
cell, may account for our ﬁnding that depletion of LRP/LR does not
totally impede nucleic transport of the mutant PrP. This issue shall be
further addressed in cell biology studies to unravel the yet unidentiﬁed
mode of action by which mutant PrP is transported into the nucleus.
4.3. Subcellular Localization of the mutant prion protein lacking the
signal peptide
Previously, Crozet et al. described a chromatin association for the
prion protein lacking its signal peptide [18]. However, the chromatin-
removal method has some limitations which might not reveal reliable
information on localization in vivo [39]. Here, we performed an
additional colocalization experiment by the use of the DNA stain DAPI
to conﬁrm the chromatin association of mutant PrP. Astonishingly, we
could barely ﬁnd a colocalization of DAPI stained DNA with DsRed-
ΔSP-PrP. This ﬁnding clearly argues against a tight chromatin binding
of DsRed-ΔSP-PrP, because the distance of two molecules lacking
colocalization clearly exceeds 200 nm in the x/y plane and even more
than 400 nm in the z plane. The mutant protein is found in nucleic
compartments containing a low DNA content, which may be nucleoli
structures. Therefore, further experiments, in which subnuclear
structures are speciﬁcally co-stained will be needed to investigate
the subnuclear localization of DsRed-ΔSP-PrP.
In summary,we have conﬁrmed, that EGFP-PrP is localized at the cell
surface and in a perinuclear compartment within the cell and that
mutant DsRed-ΔSP-PrP localized to the nucleus. Interestingly, we found
that the latter PrP mutant failed to be colocalized with DAPI stained
heterochromatin. Furthermore, in the present study we showed for the
ﬁrst time that (i) PrP-EGFP and LRP-DsRed colocalize in the perinuclear
compartment in addition to a cell surface-colocalization and (ii) DsRed-
ΔSP-PrP and LRP-ECFP partly colocalize in the nucleus, respectively.
Thus, the 37 kDa/67 kDa LRP/LR and the prion protein reveal close
proximity not only on the surface of eukaryotic cells but additionally in
intracellular compartments. Investigations by immunoprecipitation or
cellular fractionationwill furtherunravel the role of PrP, PrPmutants and
LRP/LR in the life cycle of prions.
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